Circulating Tumor Cell Subtypes may Predict Responses to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Circulating Tumor Cell Subtypes may Predict Responses to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Help Center Sign In Submit a Preprint Cite Share Download PDF Research article Circulating Tumor Cell Subtypes may Predict Responses to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Ge Ma, Jingyi Wang, Xingmeng Wang, Hanling Zeng, Minghui Li, Xu Han, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.2.23526/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Neoadjuvant chemotherapy (NCT) is the standard treatment for patients with locally advanced breast cancer (LABC). However, the predictive value of circulating tumor cells (CTCs) with different molecular subtypes in NCT response has not yet been determined, which was, therefore, the aim of this study. Methods: All patients were staged as LABC and received an EC×4 –T×4 NCT regimen. Blood samples were collected from patients at the time of biopsy, and after the first and eighth NCT courses. Patients were divided into High responders (High-R) and Low responders (Low-R) according to Miller-Payne system and changes in Ki-67 levels after NCT treatment. A novel SE-i•FISH strategy was applied to detect CTCs. Subtypes were successfully analyzed in LABC patients undergoing NCT, for the first time. Results: Total CTCs increased continuously and were higher for Low-R patients; while in the High-R group, total CTCs increased slightly during NCT before returning to baseline levels. Triploid and tetraploid chromosome 8 as well as the proportion of each, increased for Low-R but not High-R patients. The number of small CTCs in the Low-R group increased significantly until the last sample, however, remained constant in the High-R group. The patients with more CTCs had shorter PFS and OS than those with less CTCs after the 8th course of NCT. Conclusions: Total CTCs as well as individual subtypes within peripheral blood following NCT were predictive of patient responses to NCT. More detailed characterization of CTC blood profiles may improve predictive capacity and lead to improved LABC treatments. Cancer Biology Neoplastic cells circulating breast neoplasms neoadjuvant therapy biomarkers Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Background Breast cancer is the most common malignant tumor in women, and neoadjuvant chemotherapy (NCT) is the standard of care for patients with locally advanced breast cancer (LABC)[ 1 ]. However, a large number of patients with breast cancer respond poorly to standard treatment, and only a small number of patients achieve a complete or optimal response. In addition, chemotherapy can induce a significant, unexpected "opposite effect" that accelerates critical metastatic steps in malignancy, rather than inhibiting them[ 2 ]. Tumor heterogeneity may account for the differing therapeutic effects and should be appropriately addressed in treatment response evaluation. NCT should achieve two main objectives: shrinkage of the primary tumor and eradication of blood-borne tumor cell dissemination[ 3 ]. However, in practice due to the lack of standard testing criteria, the second objective is almost entirely overlooked by current NCT assessments despite metastasis being the primary cause of death in breast cancer patients[ 4 ]. Circulating tumor cells (CTCs) are released from the primary tumor into the blood stream and are considered to be the initiators of metastasis at distant organ sites[ 5 ]. In early breast cancer, CTC detection rates are 8–56%, according to different methods[ 6 – 8 ]. Numerous studies have demonstrated that the presence of CTCs in early breast cancer is a marker of poor prognosis[ 9 , 10 ]. In the case of LABC, The German Breast Group demonstrated that detection of CTCs prior to NCT is an independent prognostic factor of impaired clinical outcome, and is particularly effective when combined with pCR[ 11 ]. Although sufficient evidence exists to recognize the prognostic value of CTCs as an example of high-quality evidence-based medicine, complete elucidation of the quantitative changes and molecular characterization of CTCs during NCT have not been carried out, which may serve to improve the unfavorable prognoses of CTC patients. CTCs are present at very low concentrations in peripheral blood, and therefore, highly sensitive assays are required. Conventional detection strategies include two steps, enrichment and detection (or characterization). The Cell Search System is unable to effectively detect multi-functional mesenchymal CTCs while real-time PCR (RT-PCR)-based tumor cell detection methods cannot accurately measure CTC numbers by gene expression measurement[ 12 ]. Recently, a novel CTC detection strategy, subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-i•FISH) has been applied. This technique integrates both steps and achieves much higher sensitivity; negative selection, which does not limit CTC isolation to those expressing particular tumor markers, is used to enrich CTCs using the leukocyte marker CD45[ 13 ]. This system is an innovative means to detect chromosome aneuploidy with synchronous detection of the tumor biomarkers listed above. Aneuploidy may result in genomic instability[ 14 ]. In fact, several studies have described it as the most common feature of malignant tumor cells[ 15 , 16 ]. Further, using SE-i•FISH enables observation of CTC morphological features. For instance, small CTCs (< 5 µm) as well as circulating tumor microemboli (CTM; a cluster of two or more CTCs) can be distinguished from CTCs in the traditional sense. In summary, the benefits of SE-i•FISH include not only improved enumeration of CTCs, but also more detailed characterization and analytical opportunities that may be investigated during NCT assessments. The aim of this study was to evaluate the predictive power of different CTC subtypes with respect to LABC patients receiving NCT. Further, we explore the future prospects for liquid biopsy and characterization of CTC heterogeneity in NCT. Materials And Methods Patients and sample collection Written, informed consent was obtained from all patients prior to enrolment in the study. All procedures were approved by Institutional Review Boards of the First Affiliated Hospital with Nanjing Medical University. A total of 45 patients diagnosed with LABC were enrolled at the First Affiliated Hospital of Nanjing Medical University from October 2016 to November 2017. Breast cancer in all patients was confirmed by core biopsy. The pathological report, including histological type, hormone receptors, HER-2 status, and Ki-67 index were provided by the Pathology Department of the First Affiliated Hospital of Nanjing Medical University. All patients were staged as LABC and received an EC×4–T×4 NCT regimen (epirubicin 90 mg/m 2 iv d1, cyclophosphamide 600 mg/m 2 iv d1 on a 21 days cycle for four cycles, then docetaxel 80 mg/m 2 iv d1, on a 21 days cycle for four cycles). Blood samples (6 mL) were collected for CTC detection pre-treatment (at time of biopsy) and after the first and eighth courses of chemotherapy. Complete blood counts (lymphocyte, neutrophils and platelets) referred to the blood cell analysis reported by Clinical Laboratory of the First Affiliated Hospital of Nanjing Medical University. All patients with breast cancer underwent surgery. The Ki-67 values from the postoperative and preoperative biopsy pathology reports were compared and used to evaluate the NCT response. All patients were assigned to one of two groups, those in the Low-Responder (Low-R) group had a higher Ki-67 index following NCT, compared to the 66.67% basal Ki-67 value prior to NCT; alternatively, the High-Responder (High-R) group had a lower Ki-67 index. Additionally, the Miller-Payne system was applied for NCT response classification[17]. Immunofluorescence staining and SE-i•FISH In this study, we applied the subtraction enrichment (SE) and immunostaining-FISH, i•FISH ® platform for CTC detection and characterization[18, 19]. Experiments were performed according to the operation manual (Cytelligen, San Diego, CA, USA). Briefly, peripheral blood and cerebrospinal fluid were collected into Cytelligen tubes containing ACD anti-coagulant (Becton Dickinson, Franklin Lakes, NJ, USA) and centrifuged at 450 × g for 5 min. All sedimented cells were subsequently loaded onto the top of 3 mL non-hematopoietic cell separation matrix for immediate processing by density gradient centrifugation. Supernatants above the red blood cell layer were collected and incubated with a cocktail including anti-leukocyte antibody (CD45) immunomagnetic beads at 23-25 °C for 15 min with gentle shaking. Subsequently, the solution was subjected to magnetic separation. The bead free solution was spun at 500 × g for 2 min. Sedimented cells were thoroughly mixed with cell fixative and applied to coated CTC slides for subsequent i•FISH analysis. Air-dried samples on coated CTC slides were hybridized with centromere probe 8 (CEP8) (Abbott Laboratories, abott Park, IL, USA) for 3 h, followed by antibody staining by incubation with Alexa Fluor (AF) 594-anti-CD45, Cy5-anti-EpCAM (epithelial cell adhesion marker), Cy7-anti-vimentin, and AF488-anti-CD31 at room temperature for 30 min. Metafer- i•FISH ® automated CTC 3D scanning and image analysis Image capture, as well as CTC identification and analysis were performed using the automated Metafer- i•FISH ® ­ CTC 3D scanning and analyzing system (Carl Zeiss, Oberkochen, Germany; MetaSystems, Altlussheim, Germany; and Cytelligen, San Diego, CA, USA). Briefly, CTC slides loaded onto a fluorescence microscope (AXIO Imager Z2) stage were subjected to automated full X-Y plane scanning with cross Z-sectioning of all cells performed at a 1 mm step depth, with fluorescence signal acquisition of all color channels. Automated image processing, classification, and statistical analysis were performed to comprehensively evaluate cell size, cell cluster, tumor biomarker expression, and chromosome ploidy. A cell was judged to be CTC if it matched either of the following criteria: (1) DAPI + CD45 - CD31 - EpCAM +/- vimentin +/- chromosome 8 (Chr8) aneuploidy or polyploidy (2) DAPI + CD45 - CD31 - chr8 diploidy/minimum one tumor biomarker(s) + Statistical analysis Results are expressed as the mean ± SD. The number of CTCs and different subtypes were analyzed by repetitive measurement deviation analysis between the High-R and Low-R groups. Multiple comparison analysis corrected by Tukey’s test was used to analyze the differences within groups. Chi-square analysis was used to determine the CTC positive rates in patients with different clinicopathological features. To evaluate the predictive value of CTC occurrence in distinguishing chemotherapy-resistant patients from sensitive ones, we plotted receiver operating characteristic (ROC) curves and calculated the area under the curves (AUCs). The ROC curves of total and subtype CTC numbers were generated at three time points. The ∆ value, defined as the difference between the two measurements, was also analyzed by ROC curve. Correlation coefficients of two variables were calculated with Pearson analysis. Survival analysis was performed using Log-rank test. All statistical analyses were performed with SPSS version 21.0 (SPSS, IBM; Chicago, IL, USA), and all p values were two-tailed with 5% significance levels. Results Establishment of SE-i•FISH for breast cancer CTCs in situ phenotype and karyotype identification SE-i•FISH was optimized to monitor breast cancer CTCs expressing tumor biomarkers and Chr8 aneuploidy. Immunofluorescence staining of CTCs and CECs with anti-EpCAM and mesenchymal marker vimentin showed distinct intracellular staining for both EpCAM and vimentin. (Fig. 1 ). Analysis of CTCs detected by patient classification The CTC positive detection rate was 43/45 in LABC patients (95.6%) before NCT, and 100% following the first course of NCT and post-NCT. Patients were divided into two groups according to changes in Ki-67. The High-R group was comprised of 22 patients (48.9%) and the Low-R group of 23 patients (51.1%). According to the Miller-Payne system, 8/45 patients obtained > 90% loss of tumor cells (grade 4–5), while the other 37 patients were assigned to grade 1–3. All eight grade 4–5 patients belonged to the High-R group when sorted according to Ki-67 changes. Patient clinicopathological features and their association with CTC detection are shown in Table 1 . The CTC positive rate was not correlated with age, HER-2 status, or lymph node metastasis. However, patients with more than two lymph node metastases exhibited significantly higher numbers of CTCs (repetitive measurement deviation analysis, p = 0.029). Further, during NCT, CTC numbers increased in patients with more than two metastatic lymph nodes (p < 0.001 and 0.043 for post-1st NCT and post-NCT, respectively, additional file 1, Figure S1A). Specifically, the CTC number was high only during NCT in the High-R group, yet was continuously elevated in the Low-R group. Alternatively, for patients with two or less metastatic lymph nodes, the CTC number showed a downward trend following the initial rise in the High-R group; while in the Low-R group the number was found to steadily increase (Additional file 1, Figure S1A and 1B). Table 1 CTC numbers of patients with different clinical characteristics Factors Total (No.) High-R (No.) Low-R (No.) CTC number p value pre-NCT post-1st NCT post-NCT p value 1 p value 2 Total 45 22 23 Age 0.181 < 0.001 0.545 < 50 22 13 9 8.18 ± 7.82 111.18 ± 160.25 32.55 ± 45.48 ≥ 50 23 9 14 6.44 ± 5.53 49.78 ± 63.22 66.91 ± 93.04 Her-2 status 0.848 0.001 0.111 Negative 28 14 14 6.72 ± 6.18 70.14 ± 130.58 40.28 ± 61.69 Positive 17 8 9 8.31 ± 7.73 97.31 ± 110.92 67.94 ± 94.06 Molecular subtype 0.815 0.002 0.117 Hormone + Her-2-/+ 33 17 16 7.30 ± 6.82 58.49 ± 76.48 47.12 ± 77.27 TNBC 10 4 6 7.25 ± 6.74 138.42 ± 196.83 58.33 ± 70.71 Hormone-Her-2+ 2 1 1 8.50 ± 3.54 140.00 ± 195.16 124.00 ± 4.24 Lymph node 0.100 2 22 8 14 8.05 ± 6.76 115.81 ± 166.65 67.57 ± 89.14 P value1: different timepoints P value2: clinical characteristics CTC numbers analyzed by patient group: correlation with NCT effect A typical fluorescent photograph of a CTC is shown in Fig. 2 A. Generally, the number of CTCs increased after the first NCT cycle compared to pre-NCT levels (p < 0.001). This trend continued post-NCT (p = 0.001, Fig. 2 B). The number of CTCs was higher in the Low-R group (repetitive measurement deviation analysis, p = 0.042). There were no significant differences in CTC number between High-R and Low-R groups before NCT or after the first course of NCT (Fig. 2 C). However, following the eighth NCT course, the difference between the two groups was significant (p = 0.028). The CTC number increased slightly (p = 0.051), then decreased to baseline in the High-R group, while in the Low-R group, the number of CTCs continuously increased continuously during NCT (Fig. 2 D). According to the Miller-Payne system, the CTC number of grade 1–3 patients increased significantly and continuously following all NCT courses compared to grade 4–5 patients (Fig. 2 E and 2 F). Chromosome 8 karyotype changes between patients with different NCT responses The existence of heterogeneous polysomic Chr8 confirmed the marked heterogeneity of breast cancer CTCs (Fig. 3 A); while the ratios of CTCs with different Chr8 ploidies changed during treatment (Fig. 3 B). The frequencies of CTCs with triploid Chr8 copy numbers were 28, 34, and 45% at the three successive time points, and the corresponding tetraploid Chr8 numbers were 14, 27, and 24%, respectively. Analysis of the occurrence of triploid, tetraploid, pentaploid, or higher Chr8 copies in CTCs according to NCT response showed that the number of CTCs containing Chr8 triploidy and tetraploidy was higher in the Low-R group than in the High-R group following NCT, however, this effect was not observed pre- or post-initial NCT (p = 0.017 and 0.009 for triploidy and tetraploidy, respectively, Fig. 3 C and 3 G). Compared to the CTC number before NCT, an increase in Chr8 triploidy and tetraploidy was observed in the Low-R group post-first NCT (p = 0.003 and 0.010, respectively) and post-NCT (p = 0.002 both in triploid and tetraploid Chr8); while in the High-R group, Chr8 triploidy only increased post-first NCT, after which it returned to baseline. No increase in tetraploid Chr8 was observed in CTCs following NCT in High-R group (Fig. 3 D and 3 H). Moreover, no significant differences were observed between the Low-R and High-R groups during NCT in the numbers of multiploid (≥ pentasomy 8) CTCs for either of the time points (Fig. 3 K). Following NCT, the number and proportion of triploid and tetraploid CTCs rose continuously in only the Low-R group, not the High-R group. In addition, no significant intragroup differences were observed in multiploid CTCs (Fig. 3 L). When patients were classified by the Miller-Payne system, the trends observed in CTC Chr8 triploidy, tetraploidy and multiploid variations were similar to the ki-67 group mode (Fig. 3 E-F, I-J, M-N). Correlation of the number of small size CTCs with NCT response A vimentin + small size CTC is depicted in Fig. 4 A (left). The number of small CTCs (< 5 µm) increased after the first NCT cycle (p < 0.001), after which it remained elevated post-NCT (p = 0.001), consistent with the overall changes observed in CTCs (Fig. 4 B). Further, the number of small CTCs in Low-R patients was significantly higher during the final time point after the eighth course of NCT (p = 0.038; Fig. 4 C). This difference, however, reflected growth in the number of small CTCs after the first course (p = 0.010), which then plateaued at a comparatively high level (p = 0.003). Unlike the Low-R group, the CTC level of the High-R group remained approximately constant throughout the NCT process (Fig. 4 D). The percentage of small CTCs in the High-R group were 30.5%, 30.4%, and 35.9%, respectively, at the three timepoints (Fig. 4 G). The corresponding data for the Low-R group were 14.5%, 32.3%, and 46.7%. Additionally, the patients designated as Miller-Payne grade 1–3 exhibited the same trend in variation as that observed in the Low-R group, while grade 4–5 was observed to be the same as the High-R group (Fig. 4 E-F). CTM of LABC patients during NCT A vimentin + CTM is depicted in Fig. 4 A (right). No significant changes were observed in CTM numbers following the eighth course of NCT (repetitive measurement deviation analysis). However, the results in Low-R patients following the first course of treatment showed apparently higher numbers of CTM compared to those before NCT (Fig. 4 I). No significant differences were observed between High-R and Low-R groups at the other timepoints; the CTM increase in the Low-R group only slightly exceeded the significance level (p ≤ 0.05) at the second time point, post-first course (p = 0.067) (Fig. 4 H). CTC, mesenchymal phenotypes, and NCT sensitivity Next, CTCs were grouped according to the presence or absence of the mesenchymal marker vimentin (Fig. 5 A). The number of total and small vimentin − CTCs increased during NCTl. Further, the vimentin + CTCs increased after the first NCT course, and decreased after the last course, whereas small vimentin + CTCs increased after the first course, then remained approximately constant (Fig. 5 B and 5 C). Patients in the Low-R group displayed higher numbers of vimentin − CTCs and small CTCs after NCT (p = 0.060 and 0.038 for CTCs and small CTCs, respectively, Fig. 5 H and 5 J). Conversely, no difference was found in vimentin + CTCs, while an increased number of vimentin + small CTCs was detected in the High-R group following the first course of NCT (Fig. 5 D and 5 F). Further, vimentin − CTCs remained constant over the course of NCT treatment in the High-R group and increased in the Low-R group at which level it remained relatively constant until surgery (p = 0.002 and 0.008 for the first and eighth courses of NCT, respectively, Fig. 5 I). In contrast, vimentin + CTCs showed no significant changes during NCT (Fig. 5 E). In terms of vimentin + small CTCs, no significant changes in number were detected in the Low-R group during NCT. In contrast, vimentin + small CTCs increased post-first NCT course after which they returned to baseline in the High-R group (Fig. 5 G). Vimentin − small CTCs showed no significant change in the High-R group, but in the Low-R group an obvious increase was observed after the first course of NCT, then levels remained high (Fig. 5 K). Cumulatively, these data indicate a possible correlation between low response to NCT and increased vimentin − CTCs with no reduction in vimentin + CTC numbers. The proportion of total vimentin − CTCs confirmed this conclusion. In the Low-R group, the percentage of vimentin − small CTCs rose from 10% before NCT to 46% after completion (Fig. 5 L). Correlation between CTCs and non-cancer cells (lymphocyte, neutrophils and platelets), CTCs and cancer biomarkers during NCT The relationships between aneuploid CTCs and non-cancer cells (lymphocyte, neutrophils and platelets) were shown in Fig S2 (Additional file 2). The number of CTCs was positively correlated with neutrophils (p = 005, r = 0.416) and platelets (p = 0.421, r = 0.004) before treatment, however, these correlations were not apparent following the first course of NCT. Moreover, no correlation was observed between CTCs and the lymphocyte, tumor markers CEA, CA12-5, and CA15-3 (Additional files 2 and 3, Fig S2 and S3). Predictive value of CTC numbers ROC curve analyses indicated that the CTC total, as well as the individual subtypes, effectively predicted the NCT response after the eighth course of NCT. The AUCs for CTCs with different subtypes after the eighth course of NCT were 0.770 (95% confidence interval (CI) 0.630–0.909), 0.776 (95% CI 0.642–0.910), 0.777 (95% CI 0.640–0.913), 0.784 (95% CI 0.649–0.918), 0.772 (95% CI 0.632–0.911) and 0.792 (95% CI 0.663–0.922) for overall CTCs, small CTCs, trisomy 8 CTCs, tetrasomy 8 CTCs, vimentin − CTCs, and vimentin − small CTCs, respectively (all p values < 0.05, Fig. 6 A). Similarly, the ∆value2 (difference between the third and the first measurements) was an effective predictor of outcome. The AUCs for this measurement were 0.797 (95% CI 0.670–0.925), 0.822 (95% CI 0.702–0.942), 0.776 (95% CI 0.641–0.910), 0.804 (95% CI 0.676–0.933), 0.794 (95% CI 0.666–0.923), and 0.845 (95% CI 0.732–0.958), respectively (all p values < 0.05, Fig. 6 B). Considering the samples after only the first course of treatment, only the ∆value1 (difference between the second and the first measurements) of small vimentin − CTCs exhibited significant diagnostic value (AUC 0.566; 95% CI 0.396–0.737; Fig. 6 C). However, a lower degree of diagnostic efficiency was achieved when the Miller-Payne system was adopted, which may be related to the unbalanced sample size (Additional file 4, Fig S4). A three-year follow-up of LABC patients was conducted to evaluate the curative effects of NCT and the rationality of the surrogate endpoints including Ki-67 changes. We set the media value of CTC numbers as a threshold, and divided subjects into a CTC-High and CTC-Low group. The comparison of progression-free survival (PFS) and overall survival (OS) between the two groups was performed using Log-rank test. Results show that patients with higher CTC numbers exhibited a significantly shorter PFS and OS compared to those in the CTC-Low group after the 8th NCT course (Fig. 6 D and 6 E). In addition, we evaluated the survival of patients with High-R and Low-R (according to the Ki-67 index) and found patients in the High-R group had significantly higher PFS and OS than patients in the Low-R group (Additional file 5, Fig S5), which confirms the high reliability of the grouping methods. Discussion Liquid biopsy is the focus of precision oncology as it is noninvasive and can be repeated at multiple time points, facilitating the monitoring of disease courses and therapy selection[ 20 ]. However, the predictive value of CTCs for NCT response remains controversial. CTC detection clinical trials based on the CellSearch® system suggested EpCAM-positive CTC counts were not correlated to pCR in NCT[ 21 , 22 ]. Our previous study demonstrated that systemic adjuvant chemotherapy had a significant impact on CTCs, as assessed via RT-PCR, and this effect was observed after three cycles of chemotherapy[ 7 ]. The data also indicated the decline of CTC positive rates in NCT, which emboldened the rationale for use of CTCs as a biomarker in NCT response monitoring[ 23 ]. These inconsistent results may be due to the use of different detection platforms. Mego and colleagues measured CTC by CellSearch® or AdnaTest™ and their results demonstrated that epithelial-mesenchymal transition (EMT) phenotype CTCs may occur in the peripheral circulation of patients, and NCT is unable to eliminate CTCs undergoing EMT[ 24 ]. In the present study, the SE-i•FISH® platform was used for CTC detection and characterization. Recently, this method has been validated for detection of various rare tumor cells including CTCs and cerebrospinal tumors[ 25 – 28 ]. SE-i•FISH® effectively isolates CTCs without hypotonic damage and detects different CTC subtypes regardless of size variation and epithelial or mesenchymal phenotypes. In this study, the positive CTC rate is similar to the results presented by Camara and colleague[ 29 ], yet higher than those reported by other researchers[ 30 , 31 ]. Several factors may account for this discrepancy. First, our results proved Fisher’s theory that hematogenous metastasis could be found in early phase breast cancer, as it is a systematic disease[ 32 , 33 ]. The patients enrolled in this study were diagnosed at the locally advanced stage, making the presence of CTCs extremely likely. Secondly, the SE-i•FISH® platform detected CTCs by various tumor markers and chromosome karyotype, which should improve the overall detection rate. The high sensitivity of this technique has been verified in other malignancies including cancers of the liver, lung, colorectum, and kideys[ 25 , 28 ]. One of the most remarkable results of our study was an observed obvious increase in CTC numbers (both total and subtype) after the first course of NCT that was maintained at a high level until surgery. A similar elevation following the first course of NCT has been reported in a previous study, although different CTC capture rates existed due to the different testing methods; researchers found that CTC numbers increased concomitantly with taxane-induced tumor size-reduction[ 29 ]. More focus is placed on the changes between the baseline and post-NCT CTC numbers. A meta-analysis suggested that CTC counts decreased after NCT compared to the baseline[ 4 ]. However, this study used the CellSearch® System as the only detection method, and chemotherapy may have a substantial impact on epithelial and mesenchymal phenotypes. Hence, there were considerable differences between our SE-i•FISH® platform-based results and previous studies. Changes in proliferation are a prerequisite for changes in tumor growth rate and a decrease in the Ki-67 proliferation index during NCT is predictive of long-term benefits[ 34 , 35 ]. A large reduction in Ki-67 indicates that NCT may be effective. Alternatively, a small reduction, unchanged, or increased Ki-67 indicate that NCT may be ineffective. Some researchers have argued that although a tumor may exhibit a large initial decrease in the Ki-67 index, if it remains high after NCT there remains a high risk of recurrence[ 36 ]. Unlike the prognostic model in our earlier study, the chemotherapy response prediction model was applied in the present study. Ki-67 index fluctuation is the best group standard test to distinguish different tumor cell sensitivities to chemotherapy. The Miller-Payne system was constructed in 2003[ 17 ], and was generally accepted by oncologists. It was applied to patient groupings in this study to analyze the correlation between CTCs and clinical response. Herein, eight patients were classified as Miller-Payne grade 4 or 5 after NCT, all of whom had a high Ki-67 index reduction. By this standard, the trend in variation was the same as the Ki-67 grouping (data presented in supplementary material). However, due to the extremely uneven sample numbers (8 vs 37), further assessment is required with a larger survey sample. The comparison of CTC numbers at different time points based on chemotherapy response grouping is of high clinical value. As treatment progresses, the difference between CTC levels in High-R and Low-R groups increased. The continuous rise of CTC numbers in the Low-R group was the most notable trend. The general upward trend of CTC numbers with time may be attributed to the increase in the Low-R group in this study. Spontaneous chromosome mis-segregation events in aneuploid cells promote chromosomal instability (CIN) that can give rise to intrinsic multidrug resistance compared to CIN- cell lines[ 37 ]. Several studies have demonstrated a correlation between Chr8 ploidy in CTCs and chemotherapy resistance in different tumors[ 27 , 38 – 40 ]. In advanced gastric cancer, triploid Chr8 CTCs exhibited intrinsic drug resistance, whereas tetra- and multiploid CTCs may develop acquired resistance following chemotherapy[ 38 ]. The drug resistance character of triploid Chr8 CTCs was also observed in nasopharyngeal carcinoma[ 27 ] and locally advanced rectal cancer. To our knowledge, this study analyzed the quantity and proportion of Chr8 aneuploidy in NCT at different time points grouped by chemotherapy response for the first time in patients with LABC. During NCT, the number of triploid and tetraploid Chr8 CTCs increased only in the Low-R group. More importantly, an increasing proportion with time was found in the Low-R group. Traditional methods marked by the CellSearch® System and RT-PCR are incapable of identifying CTC size. Complementary techniques such as ISET (isolation by size of epithelial tumor cells), based on a direct size selection method for epithelial cell enrichment to further filter small CTCs may be applied to generate additional information. Research has shown the number of small CTCs is increased following chemotherapy and is accompanied by the increased ratio of drug-resistant to drug-sensitive CTCs[ 41 ]. CTMs, derived from oligoclonal groups of cells from the primary tumor, have a 23- to 50-fold increased metastatic potential compared to single CTCs[ 42 ]. In the present study, both small size CTCs and CTMs were detected; an increase in small CTCs over the course of chemotherapy was found. We attribute the overall increase of small CTC number to the increase seen in the Low-R patients. In contrast, no significant changes in CTM number occurred during NCT, indicating that CTM may have a closer relationship with metastasis than drug resistance. Some studies have indicated that CTCs with an EMT phenotype may occur in the peripheral circulation of patients with breast cancer[ 24 ]. Patients with vimentin + CTCs had worse survival rates than those with CK + CTCs[ 43 ]. In this study, results show the close relationship between vimentin- CTC numbers (large and small CTCs) and low therapy response. The proportion of vimentin- CTCs and small CTCs increased throughout the Low-R group. Notably, an increase then decrease of mesenchymal CTCs was found during NCT, especially in large CTCs of the High-R group. There is no clear explanation for this phenomenon to date. Chemotherapy could promote the EMT of primary tumor cells by multiple pathways[ 44 , 45 ] resulting in the initial increase. A study has provided evidence that EMT tumor cells modulate NK cell ligands and are vulnerable to NK-mediated cytotoxicity[ 46 ]; activation of the innate immune system may result in decreasing numbers over time. Positive correlations between CTCs and blood cells (neutrophils and platelets) were also observed before NCT. During the metastatic process, cancer cells encounter many other circulating cells. Several studies have shown that circulating platelets and neutrophils contribute to the binding of cancer cells to the endothelium and to their extravasation across the endothelial barrier[ 47 – 49 ]. However, throughout the course of NCT, this correlation disappeared due to the myelosuppression caused by chemotherapy. The diagnostic efficacy of CTCs in distinguishing different chemotherapeutic responses was tested in this study. Effective performance correlations were demonstrated for almost all indicators described based upon determinations made before surgery. However, if predicting the NCT response based only on the CTC number post-first course, the only relatively accurate indicator was the ∆value1 of vimentin- small size CTCs. The well-known SWOG S0500 clinical trial demonstrated that for patients with persistently increased CTCs after 21 days of first-line chemotherapy, early switching to an alternative cytotoxic therapy was ineffective in prolonging overall survival[ 50 ]. Our study also found low diagnostic performance after one course of chemotherapy. However, it is expected that testing over a longer timeframe will result in higher forecasting performance with this new CTC detection platform. Although surrogate endpoints including the Ki-67 and Miller-Payne system are commonly accepted, it is widely accepted that these methods carry with them a certain level of inherent risk. Therefore, in the present study, our follow-up outcome was used to evaluate the grouping methods and to overcome the skepticism. Patients with High-R showed lower recurrence than those in the Low-R. More importantly, we observed specific significant differences between PFS and OS and patients with different levels of CTCs. Cumulatively, these results confirm that CTC numbers could be used as an evaluation index for the prognosis of LABC. Conclusions During a typical NCT course specific CTC subtypes in peripheral blood may allow for rapid evaluation of NCT response. Detection at additional time points may increase the predictive capacity of CTCs to improve unfavorable outcome rates in LABC patients. Abbreviations LABC: locally advanced breast cancer; NCT: neoadjuvant chemotherapy; CTC: circulating tumor cells; SE-i•FISH: subtraction enrichment and immunostaining fluorescence in situ hybridization; PFS: progression-free survival; OS: overall survival; ROC: Receiver operating characteristic; AUC: the area under the ROC curve. Declarations Ethics approval and consent to participate Samples were collected at the First Affiliated Hospital with Nanjing Medical University. Ethics approval was obtained from the institutional ethics committee of the First Affiliated Hospital with Nanjing Medical University and written informed consent was obtained from all participants. Consent for publication All authors have given consent for publication. Availability of data and materials All remaining data and materials are available from the authors upon reasonable request. Competing interests The authors declared no potential conflicts of interest. Funding This study was funded by the Natural Science Foundation of China (81572607 and 81572602). Author Contributions: Ge Ma: conceptualization, project administration, formal analysis, writing – original draft, and writing – review and editing. Jingyi Wang: project administration and data analysis. Xingmeng Wang: data curation and methodology. Hanling Zeng: project administration and data processing. Minghui Li: writing – original draft and writing – review and editing. Xu Han: data analysis. Xinrui Mao: data analysis. Yi Jiang: data curation. Tiansong Xia: conceptualization and project administration. Xiaoan Liu: conceptualization and funding acquisition.Shui Wang: conceptualization, supervision and funding acquisition Acknowledgements The authors wish to thank all the patients and family members for participating in this study. Authors details Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, China; 2.Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China; Department of General Surgery, The First People's Hospital of Yancheng City, Yancheng, China. References Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA: a cancer journal for clinicians 2018, 68 (6):394-424. Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM: Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy . Cancer research 2008, 68 (2):516-520. Comen E, Norton L, Massague J: Clinical implications of cancer self-seeding . Nature reviews Clinical oncology 2011, 8 (6):369-377. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S et al : Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis . Journal of the National Cancer Institute 2018, 110 (6):560-567. Caixeiro NJ, Kienzle N, Lim SH, Spring KJ, Tognela A, Scott KF, de Souza P, Becker TM: Circulating tumour cells--a bona fide cause of metastatic cancer . Cancer metastasis reviews 2014, 33 (2-3):747-756. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B: The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients . Breast cancer research : BCR 2011, 13 (3):R61. Chong MH, Zhao Y, Wang J, Zha XM, Liu XA, Ling LJ, Du Q, Wang S: The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform . British journal of cancer 2012, 106 (10):1605-1610. van Dalum G, van der Stam GJ, Tibbe AG, Franken B, Mastboom WJ, Vermes I, de Groot MR, Terstappen LW: Circulating tumor cells before and during follow-up after breast cancer surgery . International journal of oncology 2015, 46 (1):407-413. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S et al : Detection of minimal residual disease in blood and bone marrow in early stage breast cancer . Cancer 2010, 116 (14):3330-3337. Nole F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N et al : Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications . Annals of oncology : official journal of the European Society for Medical Oncology 2008, 19 (5):891-897. Riethdorf S, Muller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F et al : Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial . Clinical cancer research : an official journal of the American Association for Cancer Research 2017, 23 (18):5384-5393. Andergassen U, Kolbl AC, Mahner S, Jeschke U: Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review) . Oncology reports 2016, 35 (4):1905-1915. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J et al : Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells . Science translational medicine 2013, 5 (179):179ra147. Passerini V, Ozeri-Galai E, de Pagter MS, Donnelly N, Schmalbrock S, Kloosterman WP, Kerem B, Storchova Z: The presence of extra chromosomes leads to genomic instability . Nature communications 2016, 7 :10754. Gordon DJ, Resio B, Pellman D: Causes and consequences of aneuploidy in cancer . Nature reviews Genetics 2012, 13 (3):189-203. Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint . Nature reviews Cancer 2005, 5 (10):773-785. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD: A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival . Breast (Edinburgh, Scotland) 2003, 12 (5):320-327. Lin PP: Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells . Clinical and translational medicine 2015, 4 (1):38. Lin PP, Gires O, Wang DD, Li L, Wang H: Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells . Scientific reports 2017, 7 (1):9789. Heitzer E, Haque IS, Roberts CES, Speicher MR: Current and future perspectives of liquid biopsies in genomics-driven oncology . Nature reviews Genetics 2019, 20 (2):71-88. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A, Marty M: Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial . Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14 (21):7004-7010. Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB et al : Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy . Molecular cancer therapeutics 2015, 14 (3):821-827. Kasimir-Bauer S, Bittner AK, Konig L, Reiter K, Keller T, Kimmig R, Hoffmann O: Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy . Breast cancer research : BCR 2016, 18 (1):20. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN et al : Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy . International journal of cancer 2012, 130 (4):808-816. Li X, Zhang Y, Ding J, Wang M, Li N, Yang H, Wang K, Wang D, Lin PP, Li M et al : Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis . Oncotarget 2018, 9 (2):2705-2714. Li Y, Zhang X, Gong J, Zhang Q, Gao J, Cao Y, Wang DD, Lin PP, Shen L: Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer . Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2016, 28 (6):579-588. Zhang J, Shi H, Jiang T, Liu Z, Lin PP, Chen N: Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma . BMC cancer 2018, 18 (1):1133. Ye Z, Ding Y, Chen Z, Li Z, Ma S, Xu Z, Cheng L, Wang X, Zhang X, Ding N et al : Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies . Cancer biology & therapy 2018:1-6. Camara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U, Jorke C, Rabenstein C, Untch M, Pachmann K: The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer . Annals of oncology : official journal of the European Society for Medical Oncology 2007, 18 (9):1484-1492. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V et al : Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer . Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14 (9):2593-2600. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jorke C, Hammer U, Altendorf-Hofmann A et al : Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008, 26 (8):1208-1215. Fisher B, Fisher ER: The organ distribution of disseminated 51 Cr-labeled tumor cells . Cancer research 1967, 27 (2):412-420. Fisher B, Fisher ER, Feduska N: Trauma and the localization of tumor cells . Cancer 1967, 20 (1):23-30. Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, Parodi MA, Morabito F: Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis . Oncology 2010, 79 (3-4):255-261. Li L, Han D, Wang X, Wang Q, Tian J, Yao J, Yuan L, Qian K, Zou Q, Yi W et al : Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis . Future oncology (London, England) 2017, 13 (11):1021-1034. Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M: A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients . European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2013, 39 (10):1046-1052. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M et al : Chromosomal instability confers intrinsic multidrug resistance . Cancer research 2011, 71 (5):1858-1870. Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang DD, Lin PP et al : Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer . Oncotarget 2014, 5 (16):6594-6602. Wan JF, Li XQ, Zhang J, Yang LF, Zhu J, Li GC, Liang LP, Shen LJ, Zhang H, Li J et al : Aneuploidy of chromosome 8 and mutation of circulating tumor cells predict pathologic complete response in the treatment of locally advanced rectal cancer . Oncology letters 2018, 16 (2):1863-1868. Li Y, Zhang X, Liu D, Gong J, Wang DD, Li S, Peng Z, Li Y, Wang X, Lin PP et al : Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance . Clinical cancer research : an official journal of the American Association for Cancer Research 2018, 24 (21):5261-5271. Ito H, Yamaguchi N, Onimaru M, Kimura S, Ohmori T, Ishikawa F, Sato J, Ito S, Inoue H: Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer . Oncology letters 2016, 12 (6):4720-4726. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H et al : Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis . Cell 2014, 158 (5):1110-1122. Zhang D, Zhao L, Zhou P, Ma H, Huang F, Jin M, Dai X, Zheng X, Huang S, Zhang T: Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy . Cancer cell international 2017, 17 :6. Ma G, Huang H, Li M, Li L, Kong P, Zhu Y, Xia T, Wang S: Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer . Cancer biomarkers : section A of Disease markers 2018, 22 (3):405-415. Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, Wang WJ, Chen Q, Tang F, Liu XP et al : Involvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells . Cell death and differentiation 2011, 18 (1):16-25. Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG: Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer . The Journal of clinical investigation 2018, 128 (4):1384-1396. Somasundaram R, Herlyn D: Chemokines and the microenvironment in neuroectodermal tumor-host interaction . Seminars in cancer biology 2009, 19 (2):92-96. Coupland LA, Chong BH, Parish CR: Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells . Cancer research 2012, 72 (18):4662-4671. Reymond N, d'Agua BB, Ridley AJ: Crossing the endothelial barrier during metastasis . Nature reviews Cancer 2013, 13 (12):858-870. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL et al : Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014, 32 (31):3483-3489. Additional Files Additional file 1: Figure S1: Correlation of CTCs and lymph nodes metastasis. A) CTC numbers increased in the patients with more than two lymph node metastases. A significantly higher number of CTCs was observed in patients with advanced tumors after the first course of NCT. B and C) A subgroup analysis of the correlation between CTC numbers and treatment response in patients with different tumor stages. For all patients in the Low-R group, CTC number increased continually. In the High-R group, the change in CTC number had an increase-then-decrease trend in the 0-2 metastatic lymph node subgroup. In the subgroup with more than two metastatic lymph nodes, the CTC number remained steady throughout NCT. Additional file 2: Figure S2: Correlation between CTCs and other circulating cells. Correlation between CTC and lymphocyte, neutrophils and platelets at three time points. Additional file 3: Figure S3: The correlation between CTCs and the tumor markers CEA, CA12-5, and CA15-3. Additional file 4: Figure S4: ROC curve grouped by the Miller-Payne system. A: Number and subtypes of CTCs after the eighth course of NCT. B: ∆value2 (the difference between the third and the first timepoints) of total CTCs and CTC subtypes. Additional file 5: Figure S5: PFS and OS analysis for patients in High-R and Low-R groups (Ki-67 index mode). Supplementary Files FigS3.tif FigS4.jpg FigS2.jpg FigS5.jpg FigS1.tif Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-14093","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research article","associatedPublications":[],"authors":[{"id":347350,"identity":"86ae397f-6594-4772-b897-cf0420bb727a","order_by":1,"name":"Ge Ma","email":"","orcid":"","institution":"The First Affiliated hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ge","middleName":"","lastName":"Ma","suffix":""},{"id":347351,"identity":"57ce84b6-f217-4eb6-b04a-eb1b57c35a12","order_by":2,"name":"Jingyi Wang","email":"","orcid":"","institution":"The First Affiliated Hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jingyi","middleName":"","lastName":"Wang","suffix":""},{"id":347352,"identity":"8a5b5289-221f-44e4-803d-059a027af585","order_by":3,"name":"Xingmeng Wang","email":"","orcid":"","institution":"The First Affiliated Hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xingmeng","middleName":"","lastName":"Wang","suffix":""},{"id":347353,"identity":"4c475bec-fd82-4687-9692-50bcaac1a093","order_by":4,"name":"Hanling Zeng","email":"","orcid":"","institution":"The First Affiliated Hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Hanling","middleName":"","lastName":"Zeng","suffix":""},{"id":347354,"identity":"f1b44447-6781-4fc7-8239-16e99594cf21","order_by":5,"name":"Minghui Li","email":"","orcid":"","institution":"The First Affiliated Hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Minghui","middleName":"","lastName":"Li","suffix":""},{"id":347355,"identity":"4086375b-e969-4de0-9f37-1bc465f1b329","order_by":6,"name":"Xu Han","email":"","orcid":"","institution":"The First Affiliated Hosptial with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xu","middleName":"","lastName":"Han","suffix":""},{"id":347356,"identity":"174a9516-a3f1-4d19-bf14-2033af72c0bc","order_by":7,"name":"Xinrui Mao","email":"","orcid":"","institution":"The First Affiliated Hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xinrui","middleName":"","lastName":"Mao","suffix":""},{"id":347357,"identity":"5b96f98c-c5c0-4da6-b5ff-8a80264bc7f9","order_by":8,"name":"Yi Jiang","email":"","orcid":"","institution":"The First Affiliated Hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yi","middleName":"","lastName":"Jiang","suffix":""},{"id":347358,"identity":"78c43511-c685-431f-a2b6-adf65969f520","order_by":9,"name":"Tiansong Xia","email":"","orcid":"","institution":"The First Affiliated Hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Tiansong","middleName":"","lastName":"Xia","suffix":""},{"id":347359,"identity":"2f17b371-c407-4304-a2c8-75a5956d180b","order_by":10,"name":"Xiaoan Liu","email":"","orcid":"","institution":"The First Affiliated Hospital with Nanjing Medical University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xiaoan","middleName":"","lastName":"Liu","suffix":""},{"id":347360,"identity":"9c90a2c0-5cc1-442a-a0c2-4631bdfbd9c7","order_by":11,"name":"shui wang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAy0lEQVRIiWNgGAWjYFACxsYHCQY2CWB2QgFRWpgPG3woSEtgYANpMSBKC1ua5IwPhyFaGIjRYnD+jLExj8H5PH757sQPDwwY5PnFDhDQciPH8DGPwe1iyTbezRJAhxnOnJ2AX4vZDR6QLbcTNxzj3QDSkmBwm5CW82fMpHkMzoG0bP5BnJYDaUDvGxwAadlGnC32N5KBgWyQnDizLXebRYKBBGG/SPYfBEblH7vEfuazm2/+qLCR55cmoAUdSJCmfBSMglEwCkYBdgAARHBGll/IC98AAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0001-8878-9162","institution":"The Frist Affiliated Hospital with Nanjing Medical University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"shui","middleName":"","lastName":"wang","suffix":""}],"badges":[],"createdAt":"2020-02-12 14:51:33","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.2.23526/v1","doiUrl":"https://doi.org/10.21203/rs.2.23526/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":495724,"identity":"c5bbb09f-60e4-439b-86f5-81857f4540c1","added_by":"auto","created_at":"2020-02-14 16:08:44","extension":"tif","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":894470,"visible":true,"origin":"","legend":"Detection of CTCs by SE-iFISH. \nA) A CTC with EpCAM+ vimentin- ≥ pentasomy 8. B) A small CTC with EpCAM- vimentin+ disomy 8. C) A CTM with EpCAM+ vimentin- by SE-iFISH. (WBC: red arrow).","description":"","filename":"Fig1r.tif","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig 1r.tif"},{"id":495726,"identity":"6ba40e2a-42e5-4776-ae82-8ef391960b95","added_by":"auto","created_at":"2020-02-14 16:08:44","extension":"tif","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":740636,"visible":true,"origin":"","legend":"CTC levels in patients during NCT. \nA) A typical fluorescent photograph of a CTC and three WBCs (red arrows). B) Trend in total CTCs during treatment. Measurements after the eighth course of treatment revealed more CTCs in patients receiving NCT. C) The difference in CTC numbers between the two response groups at three time points (Ki-67 index mode). There was no significant difference in number of CTCs until the first course of NCT. Low-R patients had higher levels of CTC than High-R patients before surgery. D) The CTC number increased slightly (p = 0.051) but then returned to baseline in the High-R group; in contrast, the number increased continuously during NCT in the Low-R group (Ki-67 index mode). E) The difference in CTC numbers between Miller-Payne grades 1-3, and 4-5 at three time points. There was no significant difference in CTC number until the first course NCT. Miller-Payne grade 1-3 patients had higher levels of CTCs than Miller-Payne grade 4-5 patients before surgery. F) No significant changes in CTC number were detected in the Miller-Payne 4-5 group during NCT; in contrast, the CTC number increased continuously during NCT in the grade 1-3 group.","description":"","filename":"fig2.tif","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/fig 2.tif"},{"id":495728,"identity":"7fbed206-d0f1-4a05-9e66-2422db8591be","added_by":"auto","created_at":"2020-02-14 16:08:44","extension":"tif","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":2399115,"visible":true,"origin":"","legend":"Changes in CTC numbers and proportion with different chromosome 8 karyotypes between patients with different responses to NCT. \nA) Images of CTCs with different chromosome 8 ploidies. CTC nuclei were stained with DAPI (blue) and chromosome 8 were imaged with centromere probe 8 spectrum orange (red dots). B) Quantitative composition of CTC subtypes with different chromosome 8 ploidies in entire populations of CTCs detected in High-R and Low-R groups at three time points. C) Comparison of trisomy 8 CTCs between the two response groups (Ki-67 index mode). No significant differences were observed between High-R and Low-R patients at the first two time points. The trisomy 8 CTC number increased in the Low-R group after the eighth course. D) Comparison of trisomy 8 CTC subtypes over the course of NCT (Ki-67 index mode). Compared to the CTC number before NCT, the triploid chromosome 8 CTCs increased in the Low-R group post-first NCT and post-NCT. Triploid chromosome 8 increased post-first NCT and returned to baseline level in the High-R group post-eighth NCT. E) Comparison of trisomy 8 CTCs between the two response groups. No significant differences were observed between Miller-Payne grade 4-5 and 1-3 patients at the first two time points. The trisomy 8 CTC number increased in the Miller-Payne grade 1-3 group after the eighth course. F) Compared to the CTC number before NCT, triploid chromosome 8 CTCs increased in Miller-Payne grade 1-3 patients post-first NCT and post-NCT. G) Comparison of tetrasomy 8 CTCs between the two response groups (Ki-67 index mode). The tetrasomy 8 CTC number was higher in the Low-R group than the High-R group after the eighth course. There was no difference between these two groups previously. H) Comparison of tetrasomy 8 CTC subtypes over the course of NCT (Ki-67 index mode). No increase of tetraploid chromosome 8 was observed in CTCs over the course of NCT in High-R patients. The number of CTCs with tetrasomy 8 increased significantly until the last detection in Low-R patients. I) Comparison of tetrasomy 8 CTCs between the two groups. The tetrasomy 8 CTC number was higher in the Miller-Payne grade 1-3 group than the Miller-Payne grade 4-5 group after the eighth NCT course. There was no difference between these two groups previously. J) No increase in tetraploid chromosome 8 was observed in CTCs over the course of NCT in Miller-Payne grade 4-5 patients. The number of CTCs with tetrasomy 8 increased significantly until the last detection in the Miller-Payne grade 1-3 group. K) There were no significant differences between the Low-R and High-R groups during NCT in numbers of multiploid (≥ pentasomy 8) CTCs for either of the post-NCT time points (Ki-67 index mode). L) No significant differences in multiploid (≥ pentasomy 8) CTCs within groups were detected in High-R patients and the number of multiploid (≥ pentasomy 8) CTCs increased after the first course of NCT (Ki-67 index mode). M) There were no significant differences between Miller-Payne grades 1-3, and 4-5 at three time points during NCT in numbers of multiploid (≥ pentasomy 8) CTCs for either of the post-NCT time points. N) No significant differences in multiploid (≥ pentasomy 8) CTCs within groups were detected in Miller-Payne grades 4-5 patients and the number of multiploid (≥ pentasomy 8) CTCs increased after the first course of NCT in patients of Miller-Payne grades 1-3.","description":"","filename":"Fig3.tif","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig 3.tif"},{"id":495729,"identity":"f804124e-2ff0-4010-ab7b-ec7b222ba655","added_by":"auto","created_at":"2020-02-14 16:08:45","extension":"tif","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":1162261,"visible":true,"origin":"","legend":"Correlation of small size CTCs, CTM and chemotherapeutic effect. \nA) Left, photograph of a small size CTC; Right, image of a two CTC cluster microembolus. B) Quantitative comparison of small CTCs. The number of small size CTCs continued to increase during NCT. C) Compared to the High-R group (Ki-67 index mode), the number of small CTCs in the Low-R group increased significantly after the eighth course of NCT. D) The number of small CTCs in Low-R patients rose after the first course of NCT and then remained constant at a comparatively high level. The CTC level of High-R patients remained approximately constant during NCT (Ki-67 index mode). E) Compared to the Miller-Payne grade 4-5 group, the number of small CTCs in the Miller-Payne grade 1-3 group increased significantly after the eighth course of NCT. F) The number of small CTCs in Miller-Payne grade 1-3 patients rose after the first course of NCT, then remained constant at a comparatively high level. G) Overall proportion changes and changes within response groups. The proportion of small CTCs increased during NCT. The proportion of small CTC in High-R patients rose from 30.5% to 35.9%, the change in the Low-R was from 14.5% to 46.7%. H) No significant change in CTM numbers was found for the different patient groups following NCT. I) Post-first course samples showed significantly higher CTM numbers in Low-R patients compared to pre-NCT samples. CTM numbers in the High-R group remained approximately constant during NCT.","description":"","filename":"Fig4rr.tif","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig 4rr.tif"},{"id":495732,"identity":"19174ed0-05c4-4fbe-a1f0-9a0635c7b5f4","added_by":"auto","created_at":"2020-02-14 16:08:45","extension":"tif","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":862373,"visible":true,"origin":"","legend":"CTCs with different mesenchymal phenotype exhibited different sensitivities to NCT. \nA) Images of CTCs and small size cell CTCs with vimentin+. B and C) Number of total CTCs and small CTCs with vimentin- increased during NCT. Total vimentin+ CTCs increased after the first course and decreased after the last course. Small vimentin+ CTCs increased after the -first course and then remained constant. D and F) No differences were found in vimentin+ total CTC occurrence between the two response groups. However, more vimentin+ small CTCs were detected in the High-R group after the first course of NCT. E) The number of total vimentin+ CTCs did not change during NCT. G) The vimentin+ CTC number increased post-first NCT and returned to baseline level in the High-R group. No significant changes in number were detected in the Low-R group during NCT. H and J) Patients in the Low-R group displayed higher numbers of vimentin- CTCs and small CTCs after NCT than the High-R group. I) Vimentin- CTCs remained constant in the High-R group, but in the Low-R group, increased after the first course of NCT and remained at the same high level until surgery. K) Small vimentin- CTCs showed no change in the High-R group but increased after the first course of NCT and remained at the same high level in Low-R group. L) The proportion of small CTCs with different mesenchymal phenotypes. In the Low-R group, the percentage of vimentin- small CTCs rose from 10% before NCT to 47% after all courses.","description":"","filename":"Fig5.tif","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig 5.tif"},{"id":495733,"identity":"5a2faf28-abef-459b-883e-7f4dcf25e75b","added_by":"auto","created_at":"2020-02-14 16:08:45","extension":"tif","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":395660,"visible":true,"origin":"","legend":"Receiver operating characteristic (ROC) curves for CTC numbers with different subtypes for discriminating low response from high-response and prognostic value of the CTC numbers for LABC patients. AUC: area under the curve. \nA) Number of CTCs and subtypes of CTC after the eighth course of NCT. B) ∆value2 (difference between the third and the first timepoints) of CTCs and CTC subtypes. C) The ∆value1 (difference between the second and the first timepoints) of vimentin+ small size CTCs. D) Progression-free survival analysis for LABC patients receiving NCT. E) Overall survival analysis for LABC patients receiving NCT.","description":"","filename":"Fig6.tif","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig 6.tif"},{"id":13488966,"identity":"9f0901d5-265b-4f2b-a619-d5700614da9d","added_by":"auto","created_at":"2021-09-16 22:16:58","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":4672173,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-14093/v1/b9ce563d-a4f5-41f4-bf18-d5d5e0197f4e.pdf"},{"id":495731,"identity":"63ea5ad6-afc3-4fd4-9fa7-bcdbe9849fba","added_by":"auto","created_at":"2020-02-14 16:08:45","extension":"tif","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":8509784,"visible":true,"origin":"","legend":"","description":"","filename":"FigS3.tif","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig S3.tif"},{"id":495730,"identity":"39a35a35-2690-4604-8aa0-475cdb26af51","added_by":"auto","created_at":"2020-02-14 16:08:45","extension":"jpg","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":294059,"visible":true,"origin":"","legend":"","description":"","filename":"FigS4.jpg","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig S4.jpg"},{"id":495723,"identity":"23c6e483-1946-4875-bb02-3a400e073f94","added_by":"auto","created_at":"2020-02-14 16:08:44","extension":"jpg","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":295777,"visible":true,"origin":"","legend":"","description":"","filename":"FigS2.jpg","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig S2.jpg"},{"id":495727,"identity":"36c53729-a9ef-4e80-b99c-e0ca0ba65f94","added_by":"auto","created_at":"2020-02-14 16:08:44","extension":"jpg","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":181204,"visible":true,"origin":"","legend":"","description":"","filename":"FigS5.jpg","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig S5.jpg"},{"id":495725,"identity":"a9d678a9-2d96-46ab-9853-2f7ae28666a7","added_by":"auto","created_at":"2020-02-14 16:08:44","extension":"tif","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":10273692,"visible":true,"origin":"","legend":"","description":"","filename":"FigS1.tif","url":"https://assets-eu.researchsquare.com/files/64711880-8caf-41a3-9386-862d3c319db6/v1/Fig S1.tif"}],"financialInterests":"","formattedTitle":"Circulating Tumor Cell Subtypes may Predict Responses to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","fulltext":[{"header":"Background","content":" \u003cp\u003eBreast cancer is the most common malignant tumor in women, and neoadjuvant chemotherapy (NCT) is the standard of care for patients with locally advanced breast cancer (LABC)[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. However, a large number of patients with breast cancer respond poorly to standard treatment, and only a small number of patients achieve a complete or optimal response. In addition, chemotherapy can induce a significant, unexpected \"opposite effect\" that accelerates critical metastatic steps in malignancy, rather than inhibiting them[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Tumor heterogeneity may account for the differing therapeutic effects and should be appropriately addressed in treatment response evaluation. NCT should achieve two main objectives: shrinkage of the primary tumor and eradication of blood-borne tumor cell dissemination[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. However, in practice due to the lack of standard testing criteria, the second objective is almost entirely overlooked by current NCT assessments despite metastasis being the primary cause of death in breast cancer patients[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eCirculating tumor cells (CTCs) are released from the primary tumor into the blood stream and are considered to be the initiators of metastasis at distant organ sites[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. In early breast cancer, CTC detection rates are 8\u0026ndash;56%, according to different methods[\u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Numerous studies have demonstrated that the presence of CTCs in early breast cancer is a marker of poor prognosis[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In the case of LABC, The German Breast Group demonstrated that detection of CTCs prior to NCT is an independent prognostic factor of impaired clinical outcome, and is particularly effective when combined with pCR[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Although sufficient evidence exists to recognize the prognostic value of CTCs as an example of high-quality evidence-based medicine, complete elucidation of the quantitative changes and molecular characterization of CTCs during NCT have not been carried out, which may serve to improve the unfavorable prognoses of CTC patients.\u003c/p\u003e \u003cp\u003eCTCs are present at very low concentrations in peripheral blood, and therefore, highly sensitive assays are required. Conventional detection strategies include two steps, enrichment and detection (or characterization). The Cell Search System is unable to effectively detect multi-functional mesenchymal CTCs while real-time PCR (RT-PCR)-based tumor cell detection methods cannot accurately measure CTC numbers by gene expression measurement[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Recently, a novel CTC detection strategy, subtraction enrichment and immunostaining fluorescence \u003cspan type=\"Italic\" class=\"Italic\" name=\"Emphasis\"\u003ein situ\u003c/span\u003e hybridization (SE-i\u0026bull;FISH) has been applied. This technique integrates both steps and achieves much higher sensitivity; negative selection, which does not limit CTC isolation to those expressing particular tumor markers, is used to enrich CTCs using the leukocyte marker CD45[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. This system is an innovative means to detect chromosome aneuploidy with synchronous detection of the tumor biomarkers listed above. Aneuploidy may result in genomic instability[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. In fact, several studies have described it as the most common feature of malignant tumor cells[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Further, using SE-i\u0026bull;FISH enables observation of CTC morphological features. For instance, small CTCs (\u0026lt;\u0026thinsp;5\u0026nbsp;\u0026micro;m) as well as circulating tumor microemboli (CTM; a cluster of two or more CTCs) can be distinguished from CTCs in the traditional sense. In summary, the benefits of SE-i\u0026bull;FISH include not only improved enumeration of CTCs, but also more detailed characterization and analytical opportunities that may be investigated during NCT assessments.\u003c/p\u003e \u003cp\u003eThe aim of this study was to evaluate the predictive power of different CTC subtypes with respect to LABC patients receiving NCT. Further, we explore the future prospects for liquid biopsy and characterization of CTC heterogeneity in NCT.\u003c/p\u003e "},{"header":"Materials And Methods","content":"\u003cp\u003ePatients and sample collection\u003c/p\u003e\n\u003cp\u003eWritten, informed consent was obtained from all patients prior to enrolment in the study. All procedures were approved by Institutional Review Boards of the First Affiliated Hospital with Nanjing Medical University.\u003c/p\u003e\n\u003cp\u003eA total of 45 patients diagnosed with LABC were enrolled at the First Affiliated Hospital of Nanjing Medical University from October 2016 to November 2017. Breast cancer in all patients was confirmed by core biopsy. The pathological report, including histological type, hormone receptors, HER-2 status, and Ki-67 index were provided by the Pathology Department of the First Affiliated Hospital of Nanjing Medical University. All patients were staged as LABC and received an EC\u0026times;4\u0026ndash;T\u0026times;4 NCT regimen (epirubicin 90 mg/m\u003csup\u003e2\u003c/sup\u003e iv d1, cyclophosphamide 600 mg/m\u003csup\u003e2\u003c/sup\u003e iv d1 on a 21 days cycle for four cycles, then docetaxel 80 mg/m\u003csup\u003e2\u003c/sup\u003e iv d1, on a 21 days cycle for four cycles). Blood samples (6 mL) were collected for CTC detection pre-treatment (at time of biopsy) and after the first and eighth courses of chemotherapy. Complete blood counts (lymphocyte, neutrophils and platelets) referred to the blood cell analysis reported by Clinical Laboratory of the First Affiliated Hospital of Nanjing Medical University. All patients with breast cancer underwent surgery. The Ki-67 values from the postoperative and preoperative biopsy pathology reports were compared and used to evaluate the NCT response. All patients were assigned to one of two groups, those in the Low-Responder (Low-R) group had a higher Ki-67 index following NCT, compared to the 66.67% basal Ki-67 value prior to NCT; alternatively, the High-Responder (High-R) group had a lower Ki-67 index. Additionally, the Miller-Payne system was applied for NCT response classification[17].\u003c/p\u003e\n\u003cp\u003eImmunofluorescence staining and SE-i\u0026bull;FISH\u003c/p\u003e\n\u003cp\u003eIn this study, we applied the subtraction enrichment (SE) and immunostaining-FISH, i\u0026bull;FISH\u003csup\u003e\u0026reg;\u003c/sup\u003e platform for CTC detection and characterization[18, 19]. Experiments were performed according to the operation manual (Cytelligen, San Diego, CA, USA). Briefly, peripheral blood and cerebrospinal fluid were collected into Cytelligen tubes containing ACD anti-coagulant (Becton Dickinson, Franklin Lakes, NJ, USA) and centrifuged at 450 \u0026times; \u003cem\u003eg\u003c/em\u003e for 5 min. All sedimented cells were subsequently loaded onto the top of 3 mL non-hematopoietic cell separation matrix for immediate processing by density gradient centrifugation.\u003c/p\u003e\n\u003cp\u003eSupernatants above the red blood cell layer were collected and incubated with a cocktail including anti-leukocyte antibody (CD45) immunomagnetic beads at 23-25 \u0026deg;C for 15 min with gentle shaking. Subsequently, the solution was subjected to magnetic separation. The bead free solution was spun at 500 \u0026times; \u003cem\u003eg\u003c/em\u003e for 2 min. Sedimented cells were thoroughly mixed with cell fixative and applied to coated CTC slides for subsequent i\u0026bull;FISH analysis.\u003c/p\u003e\n\u003cp\u003eAir-dried samples on coated CTC slides were hybridized with centromere probe 8 (CEP8) (Abbott Laboratories, abott Park, IL, USA) for 3 h, followed by antibody staining by incubation with Alexa Fluor (AF) 594-anti-CD45, Cy5-anti-EpCAM (epithelial cell adhesion marker), Cy7-anti-vimentin, and AF488-anti-CD31 at room temperature for 30 min.\u003c/p\u003e\n\u003cp\u003eMetafer- i\u0026bull;FISH\u003csup\u003e \u0026reg; \u003c/sup\u003eautomated CTC 3D scanning and image analysis\u003c/p\u003e\n\u003cp\u003eImage capture, as well as CTC identification and analysis were performed using the automated Metafer- i\u0026bull;FISH\u003csup\u003e\u0026reg; \u0026shy;\u003c/sup\u003eCTC 3D scanning and analyzing system (Carl Zeiss, Oberkochen, Germany; MetaSystems, Altlussheim, Germany; and Cytelligen, San Diego, CA, USA). Briefly, CTC slides loaded onto a fluorescence microscope (AXIO Imager Z2) stage were subjected to automated full X-Y plane scanning with cross Z-sectioning of all cells performed at a 1 mm step depth, with fluorescence signal acquisition of all color channels. Automated image processing, classification, and statistical analysis were performed to comprehensively evaluate cell size, cell cluster, tumor biomarker expression, and chromosome ploidy. A cell was judged to be CTC if it matched either of the following criteria:\u003c/p\u003e\n\u003cp\u003e(1) DAPI\u003csup\u003e+\u003c/sup\u003eCD45\u003csup\u003e-\u003c/sup\u003eCD31\u003csup\u003e-\u003c/sup\u003eEpCAM\u003csup\u003e+/-\u003c/sup\u003evimentin\u003csup\u003e+/-\u003c/sup\u003echromosome 8 (Chr8) aneuploidy or polyploidy\u003c/p\u003e\n\u003cp\u003e(2) DAPI\u003csup\u003e+\u003c/sup\u003eCD45\u003csup\u003e-\u003c/sup\u003eCD31\u003csup\u003e-\u003c/sup\u003echr8 diploidy/minimum one tumor biomarker(s)\u003csup\u003e+\u003c/sup\u003e\u003c/p\u003e\n\u003cp\u003eStatistical analysis\u003c/p\u003e\n\u003cp\u003eResults are expressed as the mean \u0026plusmn; SD. The number of CTCs and different subtypes were analyzed by repetitive measurement deviation analysis between the High-R and Low-R groups. Multiple comparison analysis corrected by Tukey\u0026rsquo;s test was used to analyze the differences within groups. Chi-square analysis was used to determine the CTC positive rates in patients with different clinicopathological features. To evaluate the predictive value of CTC occurrence in distinguishing chemotherapy-resistant patients from sensitive ones, we plotted receiver operating characteristic (ROC) curves and calculated the area under the curves (AUCs). The ROC curves of total and subtype CTC numbers were generated at three time points. The ∆ value, defined as the difference between the two measurements, was also analyzed by ROC curve. Correlation coefficients of two variables were calculated with Pearson analysis. Survival analysis was performed using Log-rank test. All statistical analyses were performed with SPSS version 21.0 (SPSS, IBM; Chicago, IL, USA), and all p values were two-tailed with 5% significance levels.\u003c/p\u003e"},{"header":"Results","content":" \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003cp\u003eEstablishment of SE-i\u0026bull;FISH for breast cancer CTCs in situ phenotype and karyotype identification\u003c/p\u003e \u003cp\u003eSE-i\u0026bull;FISH was optimized to monitor breast cancer CTCs expressing tumor biomarkers and Chr8 aneuploidy. Immunofluorescence staining of CTCs and CECs with anti-EpCAM and mesenchymal marker vimentin showed distinct intracellular staining for both EpCAM and vimentin. (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cp\u003e Analysis of CTCs detected by patient classification\u003c/p\u003e \u003cp\u003eThe CTC positive detection rate was 43/45 in LABC patients (95.6%) before NCT, and 100% following the first course of NCT and post-NCT.\u003c/p\u003e \u003cp\u003ePatients were divided into two groups according to changes in Ki-67. The High-R group was comprised of 22 patients (48.9%) and the Low-R group of 23 patients (51.1%). According to the Miller-Payne system, 8/45 patients obtained\u0026thinsp;\u0026gt;\u0026thinsp;90% loss of tumor cells (grade 4\u0026ndash;5), while the other 37 patients were assigned to grade 1\u0026ndash;3. All eight grade 4\u0026ndash;5 patients belonged to the High-R group when sorted according to Ki-67 changes.\u003c/p\u003e \u003cp\u003ePatient clinicopathological features and their association with CTC detection are shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. The CTC positive rate was not correlated with age, HER-2 status, or lymph node metastasis. However, patients with more than two lymph node metastases exhibited significantly higher numbers of CTCs (repetitive measurement deviation analysis, p\u0026thinsp;=\u0026thinsp;0.029). Further, during NCT, CTC numbers increased in patients with more than two metastatic lymph nodes (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001 and 0.043 for post-1st NCT and post-NCT, respectively, additional file 1, Figure S1A). Specifically, the CTC number was high only during NCT in the High-R group, yet was continuously elevated in the Low-R group. Alternatively, for patients with two or less metastatic lymph nodes, the CTC number showed a downward trend following the initial rise in the High-R group; while in the Low-R group the number was found to steadily increase (Additional file 1, Figure S1A and 1B).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cdiv class=\"SimplePara\"\u003eCTC numbers of patients with different clinical characteristics\u003c/div\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"10\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eFactors\u003c/div\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003eTotal (No.)\u003c/div\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003eHigh-R\u003c/div\u003e \u003cdiv class=\"SimplePara\"\u003e(No.)\u003c/div\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003eLow-R\u003c/div\u003e \u003cdiv class=\"SimplePara\"\u003e(No.)\u003c/div\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003eCTC number\u003c/div\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cdiv class=\"SimplePara\"\u003ep value\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003epre-NCT\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003epost-1st NCT\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003epost-NCT\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cdiv class=\"SimplePara\"\u003ep value\u003csup\u003e1\u003c/sup\u003e\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cdiv class=\"SimplePara\"\u003ep value\u003csup\u003e2\u003c/sup\u003e\u003c/div\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eTotal\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e45\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e22\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e23\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eAge\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cdiv class=\"SimplePara\"\u003e0.181\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003e\u0026lt;\u0026thinsp;0.001\u003c/span\u003e\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cdiv class=\"SimplePara\"\u003e0.545\u003c/div\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u0026lt;\u0026thinsp;50\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e22\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e13\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e9\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e8.18\u0026thinsp;\u0026plusmn;\u0026thinsp;7.82\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e111.18\u0026thinsp;\u0026plusmn;\u0026thinsp;160.25\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e32.55\u0026thinsp;\u0026plusmn;\u0026thinsp;45.48\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u0026ge;\u0026thinsp;50\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e23\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e9\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e14\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e6.44\u0026thinsp;\u0026plusmn;\u0026thinsp;5.53\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e49.78\u0026thinsp;\u0026plusmn;\u0026thinsp;63.22\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e66.91\u0026thinsp;\u0026plusmn;\u0026thinsp;93.04\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eHer-2 status\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cdiv class=\"SimplePara\"\u003e0.848\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003e0.001\u003c/span\u003e\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cdiv class=\"SimplePara\"\u003e0.111\u003c/div\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eNegative\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e28\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e14\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e14\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e6.72\u0026thinsp;\u0026plusmn;\u0026thinsp;6.18\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e70.14\u0026thinsp;\u0026plusmn;\u0026thinsp;130.58\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e40.28\u0026thinsp;\u0026plusmn;\u0026thinsp;61.69\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003ePositive\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e17\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e8\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e9\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e8.31\u0026thinsp;\u0026plusmn;\u0026thinsp;7.73\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e97.31\u0026thinsp;\u0026plusmn;\u0026thinsp;110.92\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e67.94\u0026thinsp;\u0026plusmn;\u0026thinsp;94.06\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eMolecular subtype\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cdiv class=\"SimplePara\"\u003e0.815\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003e0.002\u003c/span\u003e\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cdiv class=\"SimplePara\"\u003e0.117\u003c/div\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eHormone\u0026thinsp;+\u0026thinsp;Her-2-/+\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e33\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e17\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e16\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e7.30\u0026thinsp;\u0026plusmn;\u0026thinsp;6.82\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e58.49\u0026thinsp;\u0026plusmn;\u0026thinsp;76.48\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e47.12\u0026thinsp;\u0026plusmn;\u0026thinsp;77.27\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eTNBC\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e10\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e4\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e6\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e7.25\u0026thinsp;\u0026plusmn;\u0026thinsp;6.74\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e138.42\u0026thinsp;\u0026plusmn;\u0026thinsp;196.83\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e58.33\u0026thinsp;\u0026plusmn;\u0026thinsp;70.71\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eHormone-Her-2+\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e2\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e1\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e1\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e8.50\u0026thinsp;\u0026plusmn;\u0026thinsp;3.54\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e140.00\u0026thinsp;\u0026plusmn;\u0026thinsp;195.16\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e124.00\u0026thinsp;\u0026plusmn;\u0026thinsp;4.24\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003eLymph node\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cdiv class=\"SimplePara\"\u003e0.100\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003e\u0026lt;\u0026thinsp;0.001\u003c/span\u003e\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003e0.029\u003c/span\u003e\u003c/div\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u0026le;\u0026thinsp;2\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e23\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e14\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e9\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e6.63\u0026thinsp;\u0026plusmn;\u0026thinsp;6.77\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e48.92\u0026thinsp;\u0026plusmn;\u0026thinsp;52.36\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e34.83\u0026thinsp;\u0026plusmn;\u0026thinsp;57.57\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cdiv class=\"SimplePara\"\u003e\u0026gt;\u0026thinsp;2\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cdiv class=\"SimplePara\"\u003e22\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cdiv class=\"SimplePara\"\u003e8\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cdiv class=\"SimplePara\"\u003e14\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cdiv class=\"SimplePara\"\u003e8.05\u0026thinsp;\u0026plusmn;\u0026thinsp;6.76\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cdiv class=\"SimplePara\"\u003e115.81\u0026thinsp;\u0026plusmn;\u0026thinsp;166.65\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cdiv class=\"SimplePara\"\u003e67.57\u0026thinsp;\u0026plusmn;\u0026thinsp;89.14\u003c/div\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003eP value1: different timepoints\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003eP value2: clinical characteristics\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003eCTC numbers analyzed by patient group: correlation with NCT effect\u003c/span\u003e \u003c/p\u003e \u003cp\u003eA typical fluorescent photograph of a CTC is shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA. Generally, the number of CTCs increased after the first NCT cycle compared to pre-NCT levels (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). This trend continued post-NCT (p\u0026thinsp;=\u0026thinsp;0.001, Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB). The number of CTCs was higher in the Low-R group (repetitive measurement deviation analysis, p\u0026thinsp;=\u0026thinsp;0.042). There were no significant differences in CTC number between High-R and Low-R groups before NCT or after the first course of NCT (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). However, following the eighth NCT course, the difference between the two groups was significant (p\u0026thinsp;=\u0026thinsp;0.028). The CTC number increased slightly (p\u0026thinsp;=\u0026thinsp;0.051), then decreased to baseline in the High-R group, while in the Low-R group, the number of CTCs continuously increased continuously during NCT (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eD).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAccording to the Miller-Payne system, the CTC number of grade 1\u0026ndash;3 patients increased significantly and continuously following all NCT courses compared to grade 4\u0026ndash;5 patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eE and \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eF).\u003c/p\u003e \u003cp\u003e \u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003eChromosome 8 karyotype changes between patients with different NCT responses\u003c/span\u003e \u003c/p\u003e \u003cp\u003eThe existence of heterogeneous polysomic Chr8 confirmed the marked heterogeneity of breast cancer CTCs (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA); while the ratios of CTCs with different Chr8 ploidies changed during treatment (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB). The frequencies of CTCs with triploid Chr8 copy numbers were 28, 34, and 45% at the three successive time points, and the corresponding tetraploid Chr8 numbers were 14, 27, and 24%, respectively. Analysis of the occurrence of triploid, tetraploid, pentaploid, or higher Chr8 copies in CTCs according to NCT response showed that the number of CTCs containing Chr8 triploidy and tetraploidy was higher in the Low-R group than in the High-R group following NCT, however, this effect was not observed pre- or post-initial NCT (p\u0026thinsp;=\u0026thinsp;0.017 and 0.009 for triploidy and tetraploidy, respectively, Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC and \u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eG). Compared to the CTC number before NCT, an increase in Chr8 triploidy and tetraploidy was observed in the Low-R group post-first NCT (p\u0026thinsp;=\u0026thinsp;0.003 and 0.010, respectively) and post-NCT (p\u0026thinsp;=\u0026thinsp;0.002 both in triploid and tetraploid Chr8); while in the High-R group, Chr8 triploidy only increased post-first NCT, after which it returned to baseline. No increase in tetraploid Chr8 was observed in CTCs following NCT in High-R group (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD and \u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eH). Moreover, no significant differences were observed between the Low-R and High-R groups during NCT in the numbers of multiploid (\u0026ge;\u0026thinsp;pentasomy 8) CTCs for either of the time points (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eK). Following NCT, the number and proportion of triploid and tetraploid CTCs rose continuously in only the Low-R group, not the High-R group.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eIn addition, no significant intragroup differences were observed in multiploid CTCs (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eL). When patients were classified by the Miller-Payne system, the trends observed in CTC Chr8 triploidy, tetraploidy and multiploid variations were similar to the ki-67 group mode (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eE-F, I-J, M-N).\u003c/p\u003e \u003cp\u003e \u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003eCorrelation of the number of small size CTCs with NCT response\u003c/span\u003e \u003c/p\u003e \u003cp\u003eA vimentin\u0026thinsp;+\u0026thinsp;small size CTC is depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA (left). The number of small CTCs (\u0026lt;\u0026thinsp;5\u0026nbsp;\u0026micro;m) increased after the first NCT cycle (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), after which it remained elevated post-NCT (p\u0026thinsp;=\u0026thinsp;0.001), consistent with the overall changes observed in CTCs (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB). Further, the number of small CTCs in Low-R patients was significantly higher during the final time point after the eighth course of NCT (p\u0026thinsp;=\u0026thinsp;0.038; Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC). This difference, however, reflected growth in the number of small CTCs after the first course (p\u0026thinsp;=\u0026thinsp;0.010), which then plateaued at a comparatively high level (p\u0026thinsp;=\u0026thinsp;0.003). Unlike the Low-R group, the CTC level of the High-R group remained approximately constant throughout the NCT process (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD). The percentage of small CTCs in the High-R group were 30.5%, 30.4%, and 35.9%, respectively, at the three timepoints (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG). The corresponding data for the Low-R group were 14.5%, 32.3%, and 46.7%. Additionally, the patients designated as Miller-Payne grade 1\u0026ndash;3 exhibited the same trend in variation as that observed in the Low-R group, while grade 4\u0026ndash;5 was observed to be the same as the High-R group (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eE-F).\u003c/p\u003e \u003cp\u003e CTM of LABC patients during NCT \u003c/p\u003e \u003cp\u003eA vimentin\u0026thinsp;+\u0026thinsp;CTM is depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA (right). No significant changes were observed in CTM numbers following the eighth course of NCT (repetitive measurement deviation analysis). However, the results in Low-R patients following the first course of treatment showed apparently higher numbers of CTM compared to those before NCT (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eI). No significant differences were observed between High-R and Low-R groups at the other timepoints; the CTM increase in the Low-R group only slightly exceeded the significance level (p\u0026thinsp;\u0026le;\u0026thinsp;0.05) at the second time point, post-first course (p\u0026thinsp;=\u0026thinsp;0.067) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eH).\u003c/p\u003e \u003cp\u003e CTC, mesenchymal phenotypes, and NCT sensitivity \u003c/p\u003e \u003cp\u003eNext, CTCs were grouped according to the presence or absence of the mesenchymal marker vimentin (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA). The number of total and small vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e CTCs increased during NCTl. Further, the vimentin\u003csup\u003e+\u003c/sup\u003e CTCs increased after the first NCT course, and decreased after the last course, whereas small vimentin\u003csup\u003e+\u003c/sup\u003e CTCs increased after the first course, then remained approximately constant (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eB and \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eC). Patients in the Low-R group displayed higher numbers of vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e CTCs and small CTCs after NCT (p\u0026thinsp;=\u0026thinsp;0.060 and 0.038 for CTCs and small CTCs, respectively, Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eH and \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eJ). Conversely, no difference was found in vimentin\u003csup\u003e+\u003c/sup\u003e CTCs, while an increased number of vimentin\u003csup\u003e+\u003c/sup\u003e small CTCs was detected in the High-R group following the first course of NCT (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eD and \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eF). Further, vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e CTCs remained constant over the course of NCT treatment in the High-R group and increased in the Low-R group at which level it remained relatively constant until surgery (p\u0026thinsp;=\u0026thinsp;0.002 and 0.008 for the first and eighth courses of NCT, respectively, Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eI). In contrast, vimentin\u003csup\u003e+\u003c/sup\u003e CTCs showed no significant changes during NCT (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eE). In terms of vimentin\u003csup\u003e+\u003c/sup\u003e small CTCs, no significant changes in number were detected in the Low-R group during NCT. In contrast, vimentin\u003csup\u003e+\u003c/sup\u003e small CTCs increased post-first NCT course after which they returned to baseline in the High-R group (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eG). Vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e small CTCs showed no significant change in the High-R group, but in the Low-R group an obvious increase was observed after the first course of NCT, then levels remained high (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eK).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eCumulatively, these data indicate a possible correlation between low response to NCT and increased vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e CTCs with no reduction in vimentin\u003csup\u003e+\u003c/sup\u003e CTC numbers. The proportion of total vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e CTCs confirmed this conclusion. In the Low-R group, the percentage of vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e small CTCs rose from 10% before NCT to 46% after completion (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eL).\u003c/p\u003e \u003cp\u003e \u003cspan type=\"Bold\" class=\"Bold\" name=\"Emphasis\"\u003eCorrelation between CTCs and non-cancer cells (lymphocyte, neutrophils and platelets), CTCs and cancer biomarkers during NCT\u003c/span\u003e \u003c/p\u003e \u003cp\u003eThe relationships between aneuploid CTCs and non-cancer cells (lymphocyte, neutrophils and platelets) were shown in Fig S2 (Additional file 2). The number of CTCs was positively correlated with neutrophils (p\u0026thinsp;=\u0026thinsp;005, r\u0026thinsp;=\u0026thinsp;0.416) and platelets (p\u0026thinsp;=\u0026thinsp;0.421, r\u0026thinsp;=\u0026thinsp;0.004) before treatment, however, these correlations were not apparent following the first course of NCT. Moreover, no correlation was observed between CTCs and the lymphocyte, tumor markers CEA, CA12-5, and CA15-3 (Additional files 2 and 3, Fig S2 and S3).\u003c/p\u003e \u003cp\u003e Predictive value of CTC numbers\u003c/p\u003e \u003cp\u003eROC curve analyses indicated that the CTC total, as well as the individual subtypes, effectively predicted the NCT response after the eighth course of NCT. The AUCs for CTCs with different subtypes after the eighth course of NCT were 0.770 (95% confidence interval (CI) 0.630\u0026ndash;0.909), 0.776 (95% CI 0.642\u0026ndash;0.910), 0.777 (95% CI 0.640\u0026ndash;0.913), 0.784 (95% CI 0.649\u0026ndash;0.918), 0.772 (95% CI 0.632\u0026ndash;0.911) and 0.792 (95% CI 0.663\u0026ndash;0.922) for overall CTCs, small CTCs, trisomy 8 CTCs, tetrasomy 8 CTCs, vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e CTCs, and vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e small CTCs, respectively (all p values\u0026thinsp;\u0026lt;\u0026thinsp;0.05, Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA). Similarly, the ∆value2 (difference between the third and the first measurements) was an effective predictor of outcome. The AUCs for this measurement were 0.797 (95% CI 0.670\u0026ndash;0.925), 0.822 (95% CI 0.702\u0026ndash;0.942), 0.776 (95% CI 0.641\u0026ndash;0.910), 0.804 (95% CI 0.676\u0026ndash;0.933), 0.794 (95% CI 0.666\u0026ndash;0.923), and 0.845 (95% CI 0.732\u0026ndash;0.958), respectively (all p values\u0026thinsp;\u0026lt;\u0026thinsp;0.05, Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB). Considering the samples after only the first course of treatment, only the ∆value1 (difference between the second and the first measurements) of small vimentin\u003csup\u003e\u0026minus;\u003c/sup\u003e CTCs exhibited significant diagnostic value (AUC 0.566; 95% CI 0.396\u0026ndash;0.737; Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eC). However, a lower degree of diagnostic efficiency was achieved when the Miller-Payne system was adopted, which may be related to the unbalanced sample size (Additional file 4, Fig S4).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eA three-year follow-up of LABC patients was conducted to evaluate the curative effects of NCT and the rationality of the surrogate endpoints including Ki-67 changes. We set the media value of CTC numbers as a threshold, and divided subjects into a CTC-High and CTC-Low group. The comparison of progression-free survival (PFS) and overall survival (OS) between the two groups was performed using Log-rank test. Results show that patients with higher CTC numbers exhibited a significantly shorter PFS and OS compared to those in the CTC-Low group after the 8th NCT course (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eD and \u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eE). In addition, we evaluated the survival of patients with High-R and Low-R (according to the Ki-67 index) and found patients in the High-R group had significantly higher PFS and OS than patients in the Low-R group (Additional file 5, Fig S5), which confirms the high reliability of the grouping methods.\u003c/p\u003e "},{"header":"Discussion","content":" \u003cp\u003eLiquid biopsy is the focus of precision oncology as it is noninvasive and can be repeated at multiple time points, facilitating the monitoring of disease courses and therapy selection[\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. However, the predictive value of CTCs for NCT response remains controversial. CTC detection clinical trials based on the CellSearch\u0026reg; system suggested EpCAM-positive CTC counts were not correlated to pCR in NCT[\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Our previous study demonstrated that systemic adjuvant chemotherapy had a significant impact on CTCs, as assessed via RT-PCR, and this effect was observed after three cycles of chemotherapy[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. The data also indicated the decline of CTC positive rates in NCT, which emboldened the rationale for use of CTCs as a biomarker in NCT response monitoring[\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. These inconsistent results may be due to the use of different detection platforms. Mego and colleagues measured CTC by CellSearch\u0026reg; or AdnaTest\u0026trade; and their results demonstrated that epithelial-mesenchymal transition (EMT) phenotype CTCs may occur in the peripheral circulation of patients, and NCT is unable to eliminate CTCs undergoing EMT[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn the present study, the SE-i\u0026bull;FISH\u0026reg; platform was used for CTC detection and characterization. Recently, this method has been validated for detection of various rare tumor cells including CTCs and cerebrospinal tumors[\u003cspan additionalcitationids=\"CR26 CR27\" citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. SE-i\u0026bull;FISH\u0026reg; effectively isolates CTCs without hypotonic damage and detects different CTC subtypes regardless of size variation and epithelial or mesenchymal phenotypes. In this study, the positive CTC rate is similar to the results presented by Camara and colleague[\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e], yet higher than those reported by other researchers[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Several factors may account for this discrepancy. First, our results proved Fisher\u0026rsquo;s theory that hematogenous metastasis could be found in early phase breast cancer, as it is a systematic disease[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]. The patients enrolled in this study were diagnosed at the locally advanced stage, making the presence of CTCs extremely likely. Secondly, the SE-i\u0026bull;FISH\u0026reg; platform detected CTCs by various tumor markers and chromosome karyotype, which should improve the overall detection rate. The high sensitivity of this technique has been verified in other malignancies including cancers of the liver, lung, colorectum, and kideys[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eOne of the most remarkable results of our study was an observed obvious increase in CTC numbers (both total and subtype) after the first course of NCT that was maintained at a high level until surgery. A similar elevation following the first course of NCT has been reported in a previous study, although different CTC capture rates existed due to the different testing methods; researchers found that CTC numbers increased concomitantly with taxane-induced tumor size-reduction[\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. More focus is placed on the changes between the baseline and post-NCT CTC numbers. A meta-analysis suggested that CTC counts decreased after NCT compared to the baseline[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. However, this study used the CellSearch\u0026reg; System as the only detection method, and chemotherapy may have a substantial impact on epithelial and mesenchymal phenotypes. Hence, there were considerable differences between our SE-i\u0026bull;FISH\u0026reg; platform-based results and previous studies.\u003c/p\u003e \u003cp\u003eChanges in proliferation are a prerequisite for changes in tumor growth rate and a decrease in the Ki-67 proliferation index during NCT is predictive of long-term benefits[\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. A large reduction in Ki-67 indicates that NCT may be effective. Alternatively, a small reduction, unchanged, or increased Ki-67 indicate that NCT may be ineffective. Some researchers have argued that although a tumor may exhibit a large initial decrease in the Ki-67 index, if it remains high after NCT there remains a high risk of recurrence[\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. Unlike the prognostic model in our earlier study, the chemotherapy response prediction model was applied in the present study. Ki-67 index fluctuation is the best group standard test to distinguish different tumor cell sensitivities to chemotherapy.\u003c/p\u003e \u003cp\u003eThe Miller-Payne system was constructed in 2003[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e], and was generally accepted by oncologists. It was applied to patient groupings in this study to analyze the correlation between CTCs and clinical response. Herein, eight patients were classified as Miller-Payne grade 4 or 5 after NCT, all of whom had a high Ki-67 index reduction. By this standard, the trend in variation was the same as the Ki-67 grouping (data presented in supplementary material). However, due to the extremely uneven sample numbers (8 vs 37), further assessment is required with a larger survey sample.\u003c/p\u003e \u003cp\u003eThe comparison of CTC numbers at different time points based on chemotherapy response grouping is of high clinical value. As treatment progresses, the difference between CTC levels in High-R and Low-R groups increased. The continuous rise of CTC numbers in the Low-R group was the most notable trend. The general upward trend of CTC numbers with time may be attributed to the increase in the Low-R group in this study.\u003c/p\u003e \u003cp\u003eSpontaneous chromosome mis-segregation events in aneuploid cells promote chromosomal instability (CIN) that can give rise to intrinsic multidrug resistance compared to CIN- cell lines[\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. Several studies have demonstrated a correlation between Chr8 ploidy in CTCs and chemotherapy resistance in different tumors[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan additionalcitationids=\"CR39\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. In advanced gastric cancer, triploid Chr8 CTCs exhibited intrinsic drug resistance, whereas tetra- and multiploid CTCs may develop acquired resistance following chemotherapy[\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. The drug resistance character of triploid Chr8 CTCs was also observed in nasopharyngeal carcinoma[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e] and locally advanced rectal cancer. To our knowledge, this study analyzed the quantity and proportion of Chr8 aneuploidy in NCT at different time points grouped by chemotherapy response for the first time in patients with LABC. During NCT, the number of triploid and tetraploid Chr8 CTCs increased only in the Low-R group. More importantly, an increasing proportion with time was found in the Low-R group.\u003c/p\u003e \u003cp\u003eTraditional methods marked by the CellSearch\u0026reg; System and RT-PCR are incapable of identifying CTC size. Complementary techniques such as ISET (isolation by size of epithelial tumor cells), based on a direct size selection method for epithelial cell enrichment to further filter small CTCs may be applied to generate additional information. Research has shown the number of small CTCs is increased following chemotherapy and is accompanied by the increased ratio of drug-resistant to drug-sensitive CTCs[\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. CTMs, derived from oligoclonal groups of cells from the primary tumor, have a 23- to 50-fold increased metastatic potential compared to single CTCs[\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. In the present study, both small size CTCs and CTMs were detected; an increase in small CTCs over the course of chemotherapy was found. We attribute the overall increase of small CTC number to the increase seen in the Low-R patients. In contrast, no significant changes in CTM number occurred during NCT, indicating that CTM may have a closer relationship with metastasis than drug resistance.\u003c/p\u003e \u003cp\u003eSome studies have indicated that CTCs with an EMT phenotype may occur in the peripheral circulation of patients with breast cancer[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. Patients with vimentin\u0026thinsp;+\u0026thinsp;CTCs had worse survival rates than those with CK\u0026thinsp;+\u0026thinsp;CTCs[\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. In this study, results show the close relationship between vimentin- CTC numbers (large and small CTCs) and low therapy response. The proportion of vimentin- CTCs and small CTCs increased throughout the Low-R group. Notably, an increase then decrease of mesenchymal CTCs was found during NCT, especially in large CTCs of the High-R group. There is no clear explanation for this phenomenon to date. Chemotherapy could promote the EMT of primary tumor cells by multiple pathways[\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e, \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e] resulting in the initial increase. A study has provided evidence that EMT tumor cells modulate NK cell ligands and are vulnerable to NK-mediated cytotoxicity[\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]; activation of the innate immune system may result in decreasing numbers over time.\u003c/p\u003e \u003cp\u003ePositive correlations between CTCs and blood cells (neutrophils and platelets) were also observed before NCT. During the metastatic process, cancer cells encounter many other circulating cells. Several studies have shown that circulating platelets and neutrophils contribute to the binding of cancer cells to the endothelium and to their extravasation across the endothelial barrier[\u003cspan additionalcitationids=\"CR48\" citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. However, throughout the course of NCT, this correlation disappeared due to the myelosuppression caused by chemotherapy.\u003c/p\u003e \u003cp\u003eThe diagnostic efficacy of CTCs in distinguishing different chemotherapeutic responses was tested in this study. Effective performance correlations were demonstrated for almost all indicators described based upon determinations made before surgery. However, if predicting the NCT response based only on the CTC number post-first course, the only relatively accurate indicator was the ∆value1 of vimentin- small size CTCs. The well-known SWOG S0500 clinical trial demonstrated that for patients with persistently increased CTCs after 21 days of first-line chemotherapy, early switching to an alternative cytotoxic therapy was ineffective in prolonging overall survival[\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Our study also found low diagnostic performance after one course of chemotherapy. However, it is expected that testing over a longer timeframe will result in higher forecasting performance with this new CTC detection platform.\u003c/p\u003e \u003cp\u003eAlthough surrogate endpoints including the Ki-67 and Miller-Payne system are commonly accepted, it is widely accepted that these methods carry with them a certain level of inherent risk. Therefore, in the present study, our follow-up outcome was used to evaluate the grouping methods and to overcome the skepticism. Patients with High-R showed lower recurrence than those in the Low-R. More importantly, we observed specific significant differences between PFS and OS and patients with different levels of CTCs. Cumulatively, these results confirm that CTC numbers could be used as an evaluation index for the prognosis of LABC.\u003c/p\u003e "},{"header":"Conclusions","content":" \u003cp\u003eDuring a typical NCT course specific CTC subtypes in peripheral blood may allow for rapid evaluation of NCT response. Detection at additional time points may increase the predictive capacity of CTCs to improve unfavorable outcome rates in LABC patients.\u003c/p\u003e "},{"header":"Abbreviations","content":"\u003cp\u003eLABC: locally advanced breast cancer; NCT: neoadjuvant chemotherapy; CTC: circulating tumor cells; SE-i\u0026bull;FISH: subtraction enrichment and immunostaining fluorescence \u003cem\u003ein situ\u003c/em\u003e hybridization; PFS: progression-free survival; OS: overall survival; ROC: Receiver operating characteristic; AUC: the area under the ROC curve.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSamples were collected at the First Affiliated Hospital with Nanjing Medical University. Ethics approval was obtained from the institutional ethics committee of the First Affiliated Hospital with Nanjing Medical University and written informed consent was obtained from all participants.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors have given consent for publication.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll remaining data and materials are available from the authors upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declared no potential conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was funded by the Natural Science Foundation of China (81572607 and\u003c/p\u003e\n\u003cp\u003e81572602).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contributions:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGe Ma: conceptualization, project administration, formal analysis, writing \u0026ndash; original draft, and writing \u0026ndash; review and editing. Jingyi Wang: project administration and data analysis. Xingmeng Wang: data curation and methodology. Hanling Zeng: project administration and data processing. Minghui Li: writing \u0026ndash; original draft and writing \u0026ndash; review and editing. Xu Han: data analysis. Xinrui Mao: data analysis. Yi Jiang: data curation. Tiansong Xia: conceptualization and project administration. Xiaoan Liu: conceptualization and funding acquisition.Shui Wang: conceptualization, supervision and funding acquisition\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors wish to thank all the patients and family members for participating in this\u003c/p\u003e\n\u003cp\u003estudy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors details\u003c/strong\u003e\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003eDepartment of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, China;\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e2.Jiangsu\u0026nbsp;Key\u0026nbsp;Lab\u0026nbsp;of\u0026nbsp;Cancer\u0026nbsp;Biomarkers,\u0026nbsp;Prevention\u0026nbsp;and\u0026nbsp;Treatment,\u0026nbsp;Jiangsu\u0026nbsp;Collaborative\u0026nbsp;Innovation\u0026nbsp;Center\u0026nbsp;For\u0026nbsp;Cancer\u0026nbsp;Personalized\u0026nbsp;Medicine,\u0026nbsp;School\u0026nbsp;of\u0026nbsp;Public\u0026nbsp;Health,\u0026nbsp;Nanjing\u0026nbsp;Medical\u0026nbsp;University,\u0026nbsp;Nanjing\u0026nbsp;211166,\u0026nbsp;China;\u003c/p\u003e\n\u003col start=\"3\"\u003e\n\u003cli\u003eDepartment of General Surgery, The First People's Hospital of Yancheng City, Yancheng, China.\u003c/li\u003e\n\u003c/ol\u003e\n"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: \u003cstrong\u003eGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries\u003c/strong\u003e. \u003cem\u003eCA: a cancer journal for clinicians \u003c/em\u003e2018, \u003cstrong\u003e68\u003c/strong\u003e(6):394-424.\u003c/li\u003e\n\u003cli\u003eYamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM: \u003cstrong\u003eInduction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy\u003c/strong\u003e. \u003cem\u003eCancer research \u003c/em\u003e2008, \u003cstrong\u003e68\u003c/strong\u003e(2):516-520.\u003c/li\u003e\n\u003cli\u003eComen E, Norton L, Massague J: \u003cstrong\u003eClinical implications of cancer self-seeding\u003c/strong\u003e. \u003cem\u003eNature reviews Clinical oncology \u003c/em\u003e2011, \u003cstrong\u003e8\u003c/strong\u003e(6):369-377.\u003c/li\u003e\n\u003cli\u003eBidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eCirculating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis\u003c/strong\u003e. \u003cem\u003eJournal of the National Cancer Institute \u003c/em\u003e2018, \u003cstrong\u003e110\u003c/strong\u003e(6):560-567.\u003c/li\u003e\n\u003cli\u003eCaixeiro NJ, Kienzle N, Lim SH, Spring KJ, Tognela A, Scott KF, de Souza P, Becker TM: \u003cstrong\u003eCirculating tumour cells--a bona fide cause of metastatic cancer\u003c/strong\u003e. \u003cem\u003eCancer metastasis reviews \u003c/em\u003e2014, \u003cstrong\u003e33\u003c/strong\u003e(2-3):747-756.\u003c/li\u003e\n\u003cli\u003eMolloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B: \u003cstrong\u003eThe prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients\u003c/strong\u003e. \u003cem\u003eBreast cancer research : BCR \u003c/em\u003e2011, \u003cstrong\u003e13\u003c/strong\u003e(3):R61.\u003c/li\u003e\n\u003cli\u003eChong MH, Zhao Y, Wang J, Zha XM, Liu XA, Ling LJ, Du Q, Wang S: \u003cstrong\u003eThe dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform\u003c/strong\u003e. \u003cem\u003eBritish journal of cancer \u003c/em\u003e2012, \u003cstrong\u003e106\u003c/strong\u003e(10):1605-1610.\u003c/li\u003e\n\u003cli\u003evan Dalum G, van der Stam GJ, Tibbe AG, Franken B, Mastboom WJ, Vermes I, de Groot MR, Terstappen LW: \u003cstrong\u003eCirculating tumor cells before and during follow-up after breast cancer surgery\u003c/strong\u003e. \u003cem\u003eInternational journal of oncology \u003c/em\u003e2015, \u003cstrong\u003e46\u003c/strong\u003e(1):407-413.\u003c/li\u003e\n\u003cli\u003eKrishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eDetection of minimal residual disease in blood and bone marrow in early stage breast cancer\u003c/strong\u003e. \u003cem\u003eCancer \u003c/em\u003e2010, \u003cstrong\u003e116\u003c/strong\u003e(14):3330-3337.\u003c/li\u003e\n\u003cli\u003eNole F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eVariation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications\u003c/strong\u003e. \u003cem\u003eAnnals of oncology : official journal of the European Society for Medical Oncology \u003c/em\u003e2008, \u003cstrong\u003e19\u003c/strong\u003e(5):891-897.\u003c/li\u003e\n\u003cli\u003eRiethdorf S, Muller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003ePrognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant \"Geparquattro\" Trial\u003c/strong\u003e. \u003cem\u003eClinical cancer research : an official journal of the American Association for Cancer Research \u003c/em\u003e2017, \u003cstrong\u003e23\u003c/strong\u003e(18):5384-5393.\u003c/li\u003e\n\u003cli\u003eAndergassen U, Kolbl AC, Mahner S, Jeschke U: \u003cstrong\u003eReal-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review)\u003c/strong\u003e. \u003cem\u003eOncology reports \u003c/em\u003e2016, \u003cstrong\u003e35\u003c/strong\u003e(4):1905-1915.\u003c/li\u003e\n\u003cli\u003eOzkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eInertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells\u003c/strong\u003e. \u003cem\u003eScience translational medicine \u003c/em\u003e2013, \u003cstrong\u003e5\u003c/strong\u003e(179):179ra147.\u003c/li\u003e\n\u003cli\u003ePasserini V, Ozeri-Galai E, de Pagter MS, Donnelly N, Schmalbrock S, Kloosterman WP, Kerem B, Storchova Z: \u003cstrong\u003eThe presence of extra chromosomes leads to genomic instability\u003c/strong\u003e. \u003cem\u003eNature communications \u003c/em\u003e2016, \u003cstrong\u003e7\u003c/strong\u003e:10754.\u003c/li\u003e\n\u003cli\u003eGordon DJ, Resio B, Pellman D: \u003cstrong\u003eCauses and consequences of aneuploidy in cancer\u003c/strong\u003e. \u003cem\u003eNature reviews Genetics \u003c/em\u003e2012, \u003cstrong\u003e13\u003c/strong\u003e(3):189-203.\u003c/li\u003e\n\u003cli\u003eKops GJ, Weaver BA, Cleveland DW: \u003cstrong\u003eOn the road to cancer: aneuploidy and the mitotic checkpoint\u003c/strong\u003e. \u003cem\u003eNature reviews Cancer \u003c/em\u003e2005, \u003cstrong\u003e5\u003c/strong\u003e(10):773-785.\u003c/li\u003e\n\u003cli\u003eOgston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD: \u003cstrong\u003eA new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival\u003c/strong\u003e. \u003cem\u003eBreast (Edinburgh, Scotland) \u003c/em\u003e2003, \u003cstrong\u003e12\u003c/strong\u003e(5):320-327.\u003c/li\u003e\n\u003cli\u003eLin PP: \u003cstrong\u003eIntegrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells\u003c/strong\u003e. \u003cem\u003eClinical and translational medicine \u003c/em\u003e2015, \u003cstrong\u003e4\u003c/strong\u003e(1):38.\u003c/li\u003e\n\u003cli\u003eLin PP, Gires O, Wang DD, Li L, Wang H: \u003cstrong\u003eComprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells\u003c/strong\u003e. \u003cem\u003eScientific reports \u003c/em\u003e2017, \u003cstrong\u003e7\u003c/strong\u003e(1):9789.\u003c/li\u003e\n\u003cli\u003eHeitzer E, Haque IS, Roberts CES, Speicher MR: \u003cstrong\u003eCurrent and future perspectives of liquid biopsies in genomics-driven oncology\u003c/strong\u003e. \u003cem\u003eNature reviews Genetics \u003c/em\u003e2019, \u003cstrong\u003e20\u003c/strong\u003e(2):71-88.\u003c/li\u003e\n\u003cli\u003ePierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A, Marty M: \u003cstrong\u003eCirculating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial\u003c/strong\u003e. \u003cem\u003eClinical cancer research : an official journal of the American Association for Cancer Research \u003c/em\u003e2008, \u003cstrong\u003e14\u003c/strong\u003e(21):7004-7010.\u003c/li\u003e\n\u003cli\u003eOnstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eImproved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy\u003c/strong\u003e. \u003cem\u003eMolecular cancer therapeutics \u003c/em\u003e2015, \u003cstrong\u003e14\u003c/strong\u003e(3):821-827.\u003c/li\u003e\n\u003cli\u003eKasimir-Bauer S, Bittner AK, Konig L, Reiter K, Keller T, Kimmig R, Hoffmann O: \u003cstrong\u003eDoes primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy\u003c/strong\u003e. \u003cem\u003eBreast cancer research : BCR \u003c/em\u003e2016, \u003cstrong\u003e18\u003c/strong\u003e(1):20.\u003c/li\u003e\n\u003cli\u003eMego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eExpression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy\u003c/strong\u003e. \u003cem\u003eInternational journal of cancer \u003c/em\u003e2012, \u003cstrong\u003e130\u003c/strong\u003e(4):808-816.\u003c/li\u003e\n\u003cli\u003eLi X, Zhang Y, Ding J, Wang M, Li N, Yang H, Wang K, Wang D, Lin PP, Li M\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eClinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis\u003c/strong\u003e. \u003cem\u003eOncotarget \u003c/em\u003e2018, \u003cstrong\u003e9\u003c/strong\u003e(2):2705-2714.\u003c/li\u003e\n\u003cli\u003eLi Y, Zhang X, Gong J, Zhang Q, Gao J, Cao Y, Wang DD, Lin PP, Shen L: \u003cstrong\u003eAneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer\u003c/strong\u003e. \u003cem\u003eChinese journal of cancer research = Chung-kuo yen cheng yen chiu \u003c/em\u003e2016, \u003cstrong\u003e28\u003c/strong\u003e(6):579-588.\u003c/li\u003e\n\u003cli\u003eZhang J, Shi H, Jiang T, Liu Z, Lin PP, Chen N: \u003cstrong\u003eCirculating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma\u003c/strong\u003e. \u003cem\u003eBMC cancer \u003c/em\u003e2018, \u003cstrong\u003e18\u003c/strong\u003e(1):1133.\u003c/li\u003e\n\u003cli\u003eYe Z, Ding Y, Chen Z, Li Z, Ma S, Xu Z, Cheng L, Wang X, Zhang X, Ding N\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eDetecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies\u003c/strong\u003e. \u003cem\u003eCancer biology \u0026amp; therapy \u003c/em\u003e2018:1-6.\u003c/li\u003e\n\u003cli\u003eCamara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U, Jorke C, Rabenstein C, Untch M, Pachmann K: \u003cstrong\u003eThe relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer\u003c/strong\u003e. \u003cem\u003eAnnals of oncology : official journal of the European Society for Medical Oncology \u003c/em\u003e2007, \u003cstrong\u003e18\u003c/strong\u003e(9):1484-1492.\u003c/li\u003e\n\u003cli\u003eIgnatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003ePrognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer\u003c/strong\u003e. \u003cem\u003eClinical cancer research : an official journal of the American Association for Cancer Research \u003c/em\u003e2008, \u003cstrong\u003e14\u003c/strong\u003e(9):2593-2600.\u003c/li\u003e\n\u003cli\u003ePachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jorke C, Hammer U, Altendorf-Hofmann A\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eMonitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse\u003c/strong\u003e. \u003cem\u003eJournal of clinical oncology : official journal of the American Society of Clinical Oncology \u003c/em\u003e2008, \u003cstrong\u003e26\u003c/strong\u003e(8):1208-1215.\u003c/li\u003e\n\u003cli\u003eFisher B, Fisher ER: \u003cstrong\u003eThe organ distribution of disseminated 51 Cr-labeled tumor cells\u003c/strong\u003e. \u003cem\u003eCancer research \u003c/em\u003e1967, \u003cstrong\u003e27\u003c/strong\u003e(2):412-420.\u003c/li\u003e\n\u003cli\u003eFisher B, Fisher ER, Feduska N: \u003cstrong\u003eTrauma and the localization of tumor cells\u003c/strong\u003e. \u003cem\u003eCancer \u003c/em\u003e1967, \u003cstrong\u003e20\u003c/strong\u003e(1):23-30.\u003c/li\u003e\n\u003cli\u003eMiglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, Parodi MA, Morabito F: \u003cstrong\u003ePrognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis\u003c/strong\u003e. \u003cem\u003eOncology \u003c/em\u003e2010, \u003cstrong\u003e79\u003c/strong\u003e(3-4):255-261.\u003c/li\u003e\n\u003cli\u003eLi L, Han D, Wang X, Wang Q, Tian J, Yao J, Yuan L, Qian K, Zou Q, Yi W\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003ePrognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis\u003c/strong\u003e. \u003cem\u003eFuture oncology (London, England) \u003c/em\u003e2017, \u003cstrong\u003e13\u003c/strong\u003e(11):1021-1034.\u003c/li\u003e\n\u003cli\u003eMiglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M: \u003cstrong\u003eA prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients\u003c/strong\u003e. \u003cem\u003eEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology \u003c/em\u003e2013, \u003cstrong\u003e39\u003c/strong\u003e(10):1046-1052.\u003c/li\u003e\n\u003cli\u003eLee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eChromosomal instability confers intrinsic multidrug resistance\u003c/strong\u003e. \u003cem\u003eCancer research \u003c/em\u003e2011, \u003cstrong\u003e71\u003c/strong\u003e(5):1858-1870.\u003c/li\u003e\n\u003cli\u003eLi Y, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang DD, Lin PP\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eClinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer\u003c/strong\u003e. \u003cem\u003eOncotarget \u003c/em\u003e2014, \u003cstrong\u003e5\u003c/strong\u003e(16):6594-6602.\u003c/li\u003e\n\u003cli\u003eWan JF, Li XQ, Zhang J, Yang LF, Zhu J, Li GC, Liang LP, Shen LJ, Zhang H, Li J\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eAneuploidy of chromosome 8 and mutation of circulating tumor cells predict pathologic complete response in the treatment of locally advanced rectal cancer\u003c/strong\u003e. \u003cem\u003eOncology letters \u003c/em\u003e2018, \u003cstrong\u003e16\u003c/strong\u003e(2):1863-1868.\u003c/li\u003e\n\u003cli\u003eLi Y, Zhang X, Liu D, Gong J, Wang DD, Li S, Peng Z, Li Y, Wang X, Lin PP\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eEvolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance\u003c/strong\u003e. \u003cem\u003eClinical cancer research : an official journal of the American Association for Cancer Research \u003c/em\u003e2018, \u003cstrong\u003e24\u003c/strong\u003e(21):5261-5271.\u003c/li\u003e\n\u003cli\u003eIto H, Yamaguchi N, Onimaru M, Kimura S, Ohmori T, Ishikawa F, Sato J, Ito S, Inoue H: \u003cstrong\u003eChange in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer\u003c/strong\u003e. \u003cem\u003eOncology letters \u003c/em\u003e2016, \u003cstrong\u003e12\u003c/strong\u003e(6):4720-4726.\u003c/li\u003e\n\u003cli\u003eAceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eCirculating tumor cell clusters are oligoclonal precursors of breast cancer metastasis\u003c/strong\u003e. \u003cem\u003eCell \u003c/em\u003e2014, \u003cstrong\u003e158\u003c/strong\u003e(5):1110-1122.\u003c/li\u003e\n\u003cli\u003eZhang D, Zhao L, Zhou P, Ma H, Huang F, Jin M, Dai X, Zheng X, Huang S, Zhang T: \u003cstrong\u003eCirculating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy\u003c/strong\u003e. \u003cem\u003eCancer cell international \u003c/em\u003e2017, \u003cstrong\u003e17\u003c/strong\u003e:6.\u003c/li\u003e\n\u003cli\u003eMa G, Huang H, Li M, Li L, Kong P, Zhu Y, Xia T, Wang S: \u003cstrong\u003ePlasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer\u003c/strong\u003e. \u003cem\u003eCancer biomarkers : section A of Disease markers \u003c/em\u003e2018, \u003cstrong\u003e22\u003c/strong\u003e(3):405-415.\u003c/li\u003e\n\u003cli\u003eLi QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, Wang WJ, Chen Q, Tang F, Liu XP\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eInvolvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells\u003c/strong\u003e. \u003cem\u003eCell death and differentiation \u003c/em\u003e2011, \u003cstrong\u003e18\u003c/strong\u003e(1):16-25.\u003c/li\u003e\n\u003cli\u003eChockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG: \u003cstrong\u003eEpithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer\u003c/strong\u003e. \u003cem\u003eThe Journal of clinical investigation \u003c/em\u003e2018, \u003cstrong\u003e128\u003c/strong\u003e(4):1384-1396.\u003c/li\u003e\n\u003cli\u003eSomasundaram R, Herlyn D: \u003cstrong\u003eChemokines and the microenvironment in neuroectodermal tumor-host interaction\u003c/strong\u003e. \u003cem\u003eSeminars in cancer biology \u003c/em\u003e2009, \u003cstrong\u003e19\u003c/strong\u003e(2):92-96.\u003c/li\u003e\n\u003cli\u003eCoupland LA, Chong BH, Parish CR: \u003cstrong\u003ePlatelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells\u003c/strong\u003e. \u003cem\u003eCancer research \u003c/em\u003e2012, \u003cstrong\u003e72\u003c/strong\u003e(18):4662-4671.\u003c/li\u003e\n\u003cli\u003eReymond N, d'Agua BB, Ridley AJ: \u003cstrong\u003eCrossing the endothelial barrier during metastasis\u003c/strong\u003e. \u003cem\u003eNature reviews Cancer \u003c/em\u003e2013, \u003cstrong\u003e13\u003c/strong\u003e(12):858-870.\u003c/li\u003e\n\u003cli\u003eSmerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eCirculating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500\u003c/strong\u003e. \u003cem\u003eJournal of clinical oncology : official journal of the American Society of Clinical Oncology \u003c/em\u003e2014, \u003cstrong\u003e32\u003c/strong\u003e(31):3483-3489.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Additional Files","content":"\u003cp\u003eAdditional file 1:\u003c/p\u003e\n\u003cp\u003eFigure S1: Correlation of CTCs and lymph nodes metastasis.\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003eA) CTC numbers increased in the patients with more than two lymph node metastases. A significantly higher number of CTCs was observed in patients with advanced tumors after the first course of NCT. B and C) A subgroup analysis of the correlation between CTC numbers and treatment response in patients with different tumor stages. For all patients in the Low-R group, CTC number increased continually. In the High-R group, the change in CTC number had an increase-then-decrease trend in the 0-2 metastatic lymph node subgroup. In the subgroup with more than two metastatic lymph nodes, the CTC number remained steady throughout NCT.\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAdditional file 2:\u003c/p\u003e\n\u003cp\u003eFigure S2: Correlation between CTCs and other circulating cells. Correlation between CTC and lymphocyte, neutrophils and platelets at three time points.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAdditional file 3:\u003c/p\u003e\n\u003cp\u003eFigure S3: The correlation between CTCs and the tumor markers CEA, CA12-5, and CA15-3.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAdditional file 4:\u003c/p\u003e\n\u003cp\u003eFigure S4: ROC curve grouped by the Miller-Payne system.\u003c/p\u003e\n\u003cp\u003eA: Number and subtypes of CTCs after the eighth course of NCT.\u003c/p\u003e\n\u003cp\u003eB: ∆value2 (the difference between the third and the first timepoints) of total CTCs and CTC subtypes.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAdditional file 5:\u003c/p\u003e\n\u003cp\u003eFigure S5: PFS and OS analysis for patients in High-R and Low-R groups (Ki-67 index mode).\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Neoplastic cells, circulating; breast neoplasms; neoadjuvant therapy; biomarkers","lastPublishedDoi":"10.21203/rs.2.23526/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.2.23526/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"Background: Neoadjuvant chemotherapy (NCT) is the standard treatment for patients with locally advanced breast cancer (LABC). However, the predictive value of circulating tumor cells (CTCs) with different molecular subtypes in NCT response has not yet been determined, which was, therefore, the aim of this study.\nMethods: All patients were staged as LABC and received an EC×4 –T×4 NCT regimen. Blood samples were collected from patients at the time of biopsy, and after the first and eighth NCT courses. Patients were divided into High responders (High-R) and Low responders (Low-R) according to Miller-Payne system and changes in Ki-67 levels after NCT treatment. A novel SE-i•FISH strategy was applied to detect CTCs. Subtypes were successfully analyzed in LABC patients undergoing NCT, for the first time.\nResults: Total CTCs increased continuously and were higher for Low-R patients; while in the High-R group, total CTCs increased slightly during NCT before returning to baseline levels. Triploid and tetraploid chromosome 8 as well as the proportion of each, increased for Low-R but not High-R patients. The number of small CTCs in the Low-R group increased significantly until the last sample, however, remained constant in the High-R group. The patients with more CTCs had shorter PFS and OS than those with less CTCs after the 8th course of NCT.\nConclusions: Total CTCs as well as individual subtypes within peripheral blood following NCT were predictive of patient responses to NCT. More detailed characterization of CTC blood profiles may improve predictive capacity and lead to improved LABC treatments.","manuscriptTitle":"Circulating Tumor Cell Subtypes may Predict Responses to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2020-02-14 16:08:43","doi":"10.21203/rs.2.23526/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"f07ceced-4bc7-4504-933b-da37598a85a5","owner":[],"postedDate":"February 14th, 2020","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":58866,"name":"Cancer Biology"}],"tags":[],"updatedAt":"","versionOfRecord":[],"versionCreatedAt":"2020-02-14 16:08:43","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-14093","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"identity":"rs-14093","version":["v1"]},"buildId":"GqpaHPwrfC8PjnIFayRh5","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}